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Zusammenfassung 
Für die moderne Medizin gewinnt die Stammzellforschung zunehmend an Bedeutung. 
Mesenchymale Stammzellen (MSZ) sind multipotente adulte Stammzellen, welche in 
Adipozyten, Osteoblasten und Chondrozyten differenzieren können und immunsuppressive 
Eigenschaften besitzen. Kürzlich konnten wir verschiedene MSZ-Subtypen in der humanen 
Dermis identifizieren und isolieren, welche einzigartige Differenzierungskapazitäten 
aufwiesen und dabei eine Reihe von MSZ Markern exprimierten, die auch auf MSZ aus dem 
Knochenmark präsent sind. Aufgrund der relativ einfachen Zugänglichkeit der Haut, stellen 
MSZ in Zukunft eine interessante Möglichkeit für vielfältige Einsatzmöglichkeiten in der 
Medizin dar. Um jedoch MSZ für therapeutische Zwecke verwenden zu können, werden 
weitere Informationen über ihre funktionellen Eigenschaften benötigt. Da die Aktivität von 
Stammzellen eng mit deren Mikroumgebung zusammenhängt, haben wir MSZ-Subtypen in 
jugendlicher menschlichen Haut mittels Immunfluoreszenz-Färbungen lokalisiert. Dabei 
haben wir mehrere Zellen und Zellstrukturen gefunden, welche die typischen MSZ-Marker 
CD73, CD90 und CD271 exprimierten. Weiters fanden wir eine bevorzugte perivaskuläre 
Verteilung von CD271+ Zellen, welche häufig Kollagen Typ-IV koexprimierten. Zellen, die 
neuronale und gliale Marker aufwiesen, wurden von CD271+ Zellstrukturen umgeben. 
Vereinzelt konnten CD271+ Zellen identifiziert werden, welche diese neuralen/glialen Marker 
koexprimierten. Da bekannt ist, dass MSZ aus verschiedenen Geweben in vitro und in vivo 
immunsuppressives Potenzial aufweisen, untersuchten wir die immunsuppressiven 
Fähigkeiten spezifischer MSZ-Subtypen aus der Haut, welche mit Hilfe der Expression der 
Marker CD73, CD90 und CD271 isoliert wurden. Außerdem stellten wir uns die Frage, ob 
regulatorische T-Zellen für die Inhibierung der T-Zellproliferation verantwortlich sein können 
oder zumindest beteiligt sind. Die immunsuppressive Eigenschaft dermaler MSZ wurde in 
funktionellen in vitro Experimenten untersucht, wobei die gesamte dermale Fraktion, 
definierte dermale MSZ Populationen und, als Kontrolle, MSZ aus dem Knochenmark 
verwendet wurden. Es muss betont werden, dass keine dieser Zelltypen kostimulatorische 
Moleküle, wie CD80/86, exprimiert. Diese Zellen wurden mit CD25-depletierten, naiven T-
Helferzellen kultiviert und mit anti-CD3 oder anti-CD3/CD28 Antikörpern stimuliert. Mittels 
Durchflusszytometrie, wurde sowohl die T-Zell Proliferation mittels Carboxyfluorescein 
Succinimidylester Verdünnung visualisiert, als auch die Induktion regulatorischer T-Zellen 
durch Gegenfärbung des Transkriptionsfaktors Foxp3 evaluiert. Anti-CD3/CD28-stimulierte 
naive T-Helferzellen wiesen nach Kokultur mit Hautzellen oder MSZ aus dem Knochenmark 
nur eine marginale Erhöhung der Foxp3-Expression in T-Zellen auf, während die 
Stimulierung mit anti-CD3 alleine die Foxp3-Expression, sowohl nach Kokultur mit dermalen 
Zellen als auch mit MSZ aus dem Knochenmark, signifikant erhöhte. Außerdem 
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beobachteten wir eine, wenn auch nicht signifikante Tendenz, dass CD90+ Hautzellen mehr 
FoxP3 in T-Helferzellen induzieren als CD90-depletierte Zellen. Weiters, fanden wir einen 
höheren Anteil von Foxp3-exprimierenden T-Helferzellen nach Kokultur mit CD271-
depletierten dermalen Zellen verglichen mit CD271+-Zellen. Zusammenfassend konnten wir 
die enge Assoziation von nicht-follikulären MSZ aus humaner Haut mit dem dermalen 
Gefäßsystem demonstrieren, welches die Besiedelung einer perivaskulären Nische nahe 
legt. Diese Lokalisation lässt den Schluss zu, dass sie direkt mit Lymphozyten in der 
Peripherie interagieren können. Gemeinsam mit den funktionellen Daten weisen unsere 
Ergebnisse auf eine entscheidende Rolle für dermale MSZ zur Erhaltung der 
immunologischen Homöostase in der Haut hin, um so möglicherweise exzessive 
Immunantworten zu verhindern. 
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Abstract 
Stem cell-based therapies are anticipated to be part of modern clinical medicine. 
Mesenchymal stem cells (MSCs) are multipotent adult stem cells, which can differentiate into 
adipocytes, osteoblasts and chondrocytes and have immunosuppressive features. Recently, 
we identified and isolated different MSC subsets in human dermis, which possess unique 
differentiation capacities and express several markers known to be expressed by bone 
marrow-derived (BM-)MSCs. Given the easy accessibility of skin, resident MSCs are a very 
promising autologous source for future stem cell therapies. To make better use of dermal 
MSCs in therapies, we need a greater in-depth knowledge about their physiological role. 
Since the activity and functionality of MSCs are closely related with their microenvironment, 
we localized MSC subsets in human skin cryosections by immunofluorescence staining and 
found some cells and cell structures to be positive for MSC markers such as CD73, CD90 
and CD271. Further, we identified a preferential perivascular distribution of CD271+ cells, 
frequently coexpressing collagen type-IV. Cells expressing neuronal and glial markers were 
found to be surrounded by CD271+ cells but rarely CD271+ cells coexpressed these neural 
crest-related markers. As MSCs from various tissues are known to have immunomodulatory 
potential in vitro and in vivo, we aimed to investigate the immunosuppressive capacities of 
specific dermal-derived MSC subsets, separated via the expression of the markers CD73, 
CD90 and CD271. Further, we wanted to unravel whether regulatory T cells are involved in 
the inhibition of T cell proliferation. For this purpose, dermal MSCs were subjected to 
functional in vitro assays. Total adherent dermal cells, defined dermal MSC subsets and, as 
a control, BM-MSCs, which all lack the expression of CD80/86, were cocultured with naive 
CD25-depleted, helper T (Th) cells and stimulated with either anti-CD3 or anti-CD3/CD28 
mAbs. Using flow cytometry, T cell proliferation and potential induction of regulatory T cells 
was visualized via carboxyfluorescein succinimidyl ester dilution and counterstaining of the 
transcription factor FoxP3, respectively. We showed that stimulation of naive Th cells with 
anti-CD3/CD28 and coculture with dermal cells or BM-MSCs led to a marginal increase of 
FoxP3-expressing T cells, while stimulation with anti-CD3 alone and coculture with dermal 
cells or BM-MCSs significantly increased FoxP3 expression in T cells. Moreover, we found a 
tendency, though not significant, for CD90+ dermal cells to induce more FoxP3 in Th cells 
than CD90- cells and a higher percentage of FoxP3-expressing Th cells upon coculture with 
CD271- dermal cells compared with CD271+ cells. In summary, we uncovered a close 
association of human, non-follicular dermal MSC subsets with skin vasculature, suggesting 
their homing in a perivascular niche. This enhances the probability of a direct interaction with 
lymphocytes in the periphery. Together with the demonstration of a yet unexplored pathway 
for FoxP3 induction in naive Th cells through dermal MSC subsets without the engagement of 
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known costimulatory molecules, our data suggest a crucial role for dermal MSCs to maintain 
the immune homeostasis in skin and to prevent excessive immunopathology. 
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1 Abbreviations 
[3H]-TdR [3H]-thymidine 
7-AAD 7-amino-actinomycin D 
Ab(s) Antibody(ies) 
AF Alexa Fluor 
APC Allophycocyanine 
BM Bone marrow 
BSA Bovine serum albumin 
CCL CC-chemokine ligand 
CCR Chemokine receptor 
CD Cluster of differentiation 
CLA Common leukocyte antigen 
CLSM Confocal laser scanning microscopy 
Col-IV Collagen type IV 
DC(s) Dendritic cell(s) 
DMSO Dimethylsulfoxide 
EDTA Ethylenediaminetetraacetic acid 
ESC(s) Embryonic stem cell(s) 
FACS Fluorescence-activated cell sorter/sorting 
FCS Fetal calf serum 
FITC Fluorescein-isothiocyanate 
FoxP3 Forkhead box P3 
GFAP Glial fibrillary acidic protein 
GPI Glycophosphatidyl inositol 
Gy Gray 
HLA Human leukocyte antigen 
HSC(s) Hematopoietic stem cell(s) 
IDO Indolamin-2,3-dioxygenase 
IFN Interferon(s) 
Ig Immunoglobulin(s) 
IL Interleukin(s) 
iPS Induced pluripotent stem cells 
iTreg induced Treg 
LC(s) Langerhans cell(s) 
LNGFR Low-affinity nerve growth factor receptor 
mAb(s) Monoclonal antibody(ies) 
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MACS Magnetic cell sorting 
MHC Major histocompatibility complex 
min Minute(s) 
mm Millimeter 
MSC(s) Mesenchymal stem/stomal cell(s) 
NCAM Neural cell adhesion molecule 
NK cell Natural killer cell(s) 
nTreg(s) natural regulatory T cell(s) 
o/n Overnight 
PBMC(s) Peripheral blood mononuclear cell(s) 
PBS Phosphate-buffered saline 
PE Phycoerythrin 
PFA Paraformaldehyde 
RCF Relative centrifugal force 
RNA Ribonucleic acid 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
SC(s) Stem cell(s) 
sec Second(s) 
SKP(s) Skin-derived precursor(s) 
TCR T cell receptor(s) 
Tfh T follicular helper cell 
TGF Transforming growth factor 
Th cell(s) T helper cell(s) 
Thy-1 Thymocyte differentiation antigen-1 
TR1 T regulatory type 1 
TRAIL Tumor necrosis factor-related apoptosis-inducing ligand 
Treg(s) Regulatory T cell(s) 
-SMA Alpha-smooth muscle actin 
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2 Introduction 
2.1 The human immune system 
The human immune system is an important and powerful defense network against bacteria, 
viruses, fungi or parasites that reached its actual complexity by co-evolution in conjunction 
with its invaders. It consists of an inherited part, the innate immunity, and the flexible 
adaptive immunity, which combined act against early and proceeding infections(1). 
The innate immune system, to which the skin and all mucous membranes belong, is a non-
specific defense line against microbes and viruses. All epithelia of the body build the first 
barrier, which prevents pathogens from invading and colonizing the tissues of the body via 
physical, chemical and microbiological features. If the seal against the exterior is disrupted or 
weakened, microbes can intrude into the organism, where they either are worsted 
immediately and non-specific by cells of the innate immune system or, in case they evade, 
trigger an adaptive immune response, which is by then already “alarmed” by the innate 
activators(1, 2). Once the infection is cured, the resulting memory cells can cause a lifelong 
lasting immunity against this specific pathogen / antigen that ensures a faster and stronger 
reaction for future infections. Both systems depend on the capability to discriminate between 
“self” and “non-self”, to allow exclusive elimination of foreign pathogens, while tissues of the 
host are left unhampered(3). 
Table 1| Defense cascade of the human immune system at a glance 
Line 
of defense 
Invader’s opposition Features 
1
st
 Surface barrier 
Mechanical  – dense cell network of skin or mucosal 
epithelia 
Chemical  – antimicrobial peptides, enzymes, acidic 
body fluids 
Biological  – normal bacterial flora 
2
nd
 Innate & early adaptive 
Patrolling phagocytes (macrophages, neutrophiles), 
complement, natural killer cells; 
Antibodies secreted at epithelial surfaces, lymphocytes 
in epithelia; 
3
rd
 Adaptive Specific antibodies and lymphocytes 
(adapted from A. Abbas et al.
(1)
) 
2.1.1 Adaptive immune system 
Responses of the adaptive immune system can be separated into a humoral and a cellular 
type. The main players of the humoral immunity are antibodies (Abs) that circulate in the 
blood and lymph and are produced by B lymphocytes that interact and crosstalk with the 
global players of the cell-mediated immune response system, the T lymphocytes or T cells. 
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2.1.2 T cells 
T cells are produced in the bone marrow along with hematopoietic cells, get preselected in 
the thymus, to ensure non-reactivity to self-antigens, and spread hereafter throughout the 
body. T cells can be distinguished from other lymphocytes through their unique expression of 
the T cell receptor (TCR) on their cell surface, which is composed of an  heterodimer in 
90-99% of T cells, compared with a minute number of T cells with  chains (1-10%)(4, 5). The 
TCR is associated with non-polymorphic polypeptides ( and  chains) that constitute the 
cluster of differentiation (CD)3 complex. Early investigations in T cell signaling led to the 
hypothesis that the TCR initially transduces the signal after peptide (p)MHC binding, whereas 
recent studies out-dated these models. It was shown by mutagenesis of the immunoreceptor 
tyrosine-based activation motives (ITAMs) on the cytoplasmatic part of CD3 that the 
phosphorylation of these tyrosines is an early and mandatory step in T cell activation(6). 
Additionally, T cells own costimulatory receptor binding sites along the TCR-complex that 
interact with CD80 or CD86. For T cell activation, both receptors have to be engaged, to 
ensure specifity of the immune system, although this is controversial in literature(7). In vivo, 
this is performed by professional antigen-presenting cells (APCs), like dendritic cells (DCs), 
B cells or macrophages that express MHC class I and II, to present foreign peptides via 
pMHC complexes for initiation of adaptive immune responses of T cells(1). The simultaneous 
ligation of the costimulatory receptor molecule CD28, which is constitutively expressed on all 
T cells, with the costimulatory molecules CD80 or CD86 strongly enhances the T cell 
signaling and subsequent proliferative response(7). In vitro, one makes use of Abs directed 
against CD3 and CD28 to provide both signals and to ensure adequate stimulation of T cell 
proliferation(8). 
Basically, T cells can be divided into two different subgroups, the cytotoxic T cells and the 
helper T (Th) cells. CD8
+ cytotoxic T cells detect and destroy tumor cells and cells infected by 
viruses or other invaders via recognition of pathogen peptides presented on MHC-I 
molecules, which are present on all nucleated host cells. By contrast, Th cells that express 
the characteristic coreceptor CD4 and can therefore interact solely with MHC-II, establish 
and orchestrate immune responses via their interaction with professional APCs, cytotoxic T 
cells and macrophages, mainly via secretion of various cytokines(1, 2). 
2.1.3 Naive Th cells 
Naive Th cells bear, beneath the TCR, CD45RA, which results from alternative splicing of 
CD45(9) and classifies the cell as “naive”, compared with CD45RO-expressing cells that 
resemble memory T cells. They play a major role in the maintenance of adaptive immune 
responses by interacting with B lymphocytes or cytotoxic T cells as well as in the activation of 
cells of the innate immune system, like macrophages(1). Further, they have the ability to 
differentiate into several subsets of Th cells with different cytokine secretion patterns, 
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depending on the type of pathogen encountered. CD4+ T cells also play a major role in the 
development of autoimmune diseases, asthma, allergies or even cancer(10). As naive Th cells 
have never encountered an antigen, they preferentially colonize sites of pathogen entrance 
or circulate in the lymphatic system, including lymph nodes. The existence of two different 
subtypes of Th cells was first described by Mosmann et al., who named and distinguished 
Th1 from Th2 cells by the different expression of cytokines, primarily interferon (IFN-) and 
interleukin (IL-)4/IL-13, respectively(11). To date, the dualistic model of Th cells has been 
expanded by a broad spectrum of Th subtypes, like Th17 that secrete IL-17, Th22 expressing 
IL-22, T follicular helper (Tfh) cells that produce IL-21 and a regulatory T cell subset, which is 
thought to be involved in maintaining tolerance by secreting IL-10, IL-35 and transforming 
growth factor (TGF-)(10). The classical monolithic model of Th cell differentiation is still 
prevalent, although there is growing evidence that differentiated Th cells are not terminally 
restricted to their subtype in reference to the cytokine secretion (Fig. 1|). For most studies, 
however, where the influence of diverse cells, substances or pathogens on the differentiation 
of naive Th cells is investigated, predominantly the culture determined phenotype of Th cells 
is of note(12). Whether these Th cells are flexible and possess the plasticity to change their 
secreted cytokines or even the expression of their master regulators, is of peripheral interest 
for many questions asked, but still a very momentous finding for therapeutic implications, as 
autoimmune diseases or allergic inflammatory disorders, where special T cell subsets are 
involved, these could be switched to other, less self-reactive and thus less harmful 
subsets(10). 
 
Fig. 1| Differentiation of naive Th cells. A| The classical monolithic model of CD4
+
 T cell differentiation that 
displays the different subsets as terminally committed with specific cytokines expressed and unique master 
transcription factors. B| Emerging evidences raise the question, if a flexible model of Th cell subsets would be 
more accurate. This would suggest that different stages of differentiation could be changed in response to intrinsic 
and extrinsic signals. This flexibility would open new fields for therapeutic approaches. (adopted from O’Shea et 
al.
(10)
) 
B A 
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2.1.4 Regulatory T cells 
The border between fast, effective and potent immune responses, with subsequent 
clearance of pathogenic microorganisms and misguided deleterious effector functions 
against self proteins, which can destroy host tissues and lead to severe inflammatory 
responses (i.e. autoimmunity diseases), is very narrow and must be tightly controlled. The 
human immune system employs numerous sophisticated regulatory mechanisms to 
accomplish this indispensable balance and to maintain homeostasis. One of the most 
prominent cellular guards of peripheral tolerance are regulatory T cells (Tregs)(13), which 
control the activation and subsequent expansion of aberrant, over- or self-reactive 
lymphocytes(14). Further, Tregs suppress effectively allograft rejection, allergy and play an 
important role in tumor immunity(15). Like for Th cells in general, distinct types of Tregs exist, 
including the adaptively induced Th3 cells
(16), which produce TGF-, the IL-10 secreting T 
regulatory type 1 (TR1) and regulatory cells that are CD8+(17) and CD4-CD8-(18), which all 
acquire their regulatory functions upon specific stimulation with antigens and cytokine 
messengers. The great majority of Tregs can be described phenotypically as CD4+ T cells, 
which bear the TCR and express high levels of CD25, also known as IL-2 receptor alpha. 
As CD25 is also upregulated upon activation of T cells under neutral TCR stimulation 
conditions(19, 20), the identification of the transcription factor forkhead box P3 (FoxP3), a 
master regulator(21) of development(22) and function(21, 23) in naturally occurring (n)Tregs lead 
to a more defined picture, although the obligatory linkage of FoxP3 expression with the 
inhibitory activity is controversial in literature. Recent findings showed that activation of 
human CD4+ and CD8+ T cells subsequently leads to transient and low FoxP3 expression(24), 
without suppressive capacity. The inclusion of the extracellular marker CD127, whose low 
expression in Tregs inversely correlates with FoxP3 expression (up to 90%)(25, 26) and the 
suppressive potency, is one essential finding that helps to clearly delineate and purify nTregs 
in combination with the expression of CD4, CD25 and FoxP3. nTregs are principally 
generated in the thymus from CD4+CD25lowCD45RA+FoxP3- T cells, by a mechanism that 
requires high-affinity interactions between the TCR and self-peptide-MHC complexes 
presented by thymus-resident stromal cells(18). Further, thymic DCs(27) and/or stromal cells(14) 
are thought to regulate the positive selection of self-reactive thymocytes and induce the 
differentiation into FoxP3+ Tregs via provision of costimulatory molecules, like CD80 or 
CD86, whose ligation to the T cell molecule CD28 is essential for FoxP3 induction in the 
thymus. However, the molecular mechanisms that drive the selection and differentiation of 
nTregs in humans are still unknown and have to be elucidated in more detail. Alternatively, 
FoxP3+ expression can also be induced in naive Th cells in the periphery
(28-35) with DCs(15, 36) 
in the presence of TGF- in vitro(28, 37). Furthermore, several in vivo studies showed that the 
conversion of naive Th cells into Tregs can also occur in the periphery
(31, 38, 39). In vitro-
induced Tregs (iTregs) show the same inhibitory potential as thymus selected nTregs, but it 
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still has to be clarified, whether iTregs are functionally stable over longer periods and to what 
extend and under what conditions they are generated in vivo(14). Nevertheless, several 
factors have been identified that facilitate and enhance the differentiation of naive Th cells 
into iTregs and maintain their survival and function, although exogenous cytokines are not 
mandatory(40). Most prominent, along with the most critical factor TGF-, is the cytokine IL-2, 
which is the ligand for the receptor CD25 and has been shown in vitro(41-43) and in mouse 
models(44, 45) to be an enhancer of the TGF--induced differentiation pathway in the 
periphery, but most important, a key factor of nTreg growth and survival(46). Other members 
of the common cytokine-receptor -chain family, to which beneath IL-2 belong for instance IL-
7 or IL-15(47), may substitute partly the maintenance activity of IL-2 and might contribute to 
Treg development(48) and function(49, 50). Further, it has been shown that tryptophan 
catabolism through indolamin-2,3-dioxygenase (IDO) matures DCs, with the help of IFN-(51) 
to induce FoxP3+ Tregs in humans(52) and that retinoic acid(53) plays an auxiliary role in DC-
mediated Treg conversion in the presence of TGF-(54-57). Although many mechanisms have 
been investigated and found to be involved in adaptive Treg development, it seems that a 
great variety of rapid induction models exist in inflamed peripheral tissues(58), but also during 
normal maintenance of homeostasis, and remain elusive. 
2.2 Stem cells 
The term stem cell was originally introduced by the Russian histologist A. Maximow at the 
beginning of the 20th century(59), for describing hematopoietic progenitor or stem cells 
(HSCs), which are now known to be the initiators of a well-organized developmental 
hierarchy(60), called hematopoiesis. Generally, stem cells are defined as unspecialized cells 
with an nearly unlimited ability to renew themselves by mitotic cell divisions, even after long 
phases of inactivity. Further, they possess the plasticity to differentiate into any organ- or 
tissue-specific cell under specific conditions, induced by the microenvironment in vivo, or 
artificially in an experimental system in vitro. Stem cells can be isolated from embryonic 
[embryonic stem cells (ESCs)] and non-embryonic tissues(61), whereas the latter gives rise to 
two different stem cells, the naturally occurring somatic or adult stem cells, like HSCs or 
mesenchymal stem cells (MSCs) and the induced pluripotent stem cells (iPS) that can be 
generated from adult tissue cells, like fibroblasts. Fulfilling the criteria of long-term self-
renewal and pluripotency, as they are able to differentiate into cells of the ectoderm, 
mesoderm and endoderm, ESCs are promising candidates for cell therapy applications, like 
regenerative medicine and tissue replacement. Further, this cell type resembled for years the 
only model to investigate the mechanisms of early developmental differentiation events for 
humans. However, since the first success in culturing human-derived ESCs in vitro, they are 
a matter of debate(62), as they are derived from preimplanted embryos(63), more precisely from 
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blastocysts. Moreover, cell transplantation therapies with ESCs are still challenging, 
predominantly facing the problems of graft rejection with allogeneic cells and tumorgenicity. 
The recent achievement of K. Takahashi and coworkers in 2007, who retrovirally introduced 
four essential transcription factors (Sox2, c-Myc, Oct-3/4 and Klf4)(64) into differentiated 
somatic human cells (fibroblasts), which resulted in restored pluripotency, with cells 
exhibiting the morphology, dividing potential and expression profile of ESCs(65), could have 
solved ethical concerns and rejection problems by using patient-derived cells. Since then, the 
original experimental setup has been improved manifold, regarding safety (c-Myc is 
oncogenic and retroviral vectors are not the delivery method of choice for human studies) 
and efficiency, through worldwide extensive work in this field. But up to date the clinical use 
of iPS cells is still far away from routine applications, as transplanted iPS cells have the 
same or even higher potential to form teratomas as ESCs(66, 67). Furthermore, transcription-
factor-based reprogrammed somatic cells keep residual signatures of DNA and histone 
methylation patterns(68), which are typical of the tissue origin (fibroblasts or blood), but this 
cell type still resembles an effective tool for basic developmental research. 
2.2.1 MSCs 
Friedenstein and his colleagues(69) discovered bone marrow-resident, non-hematopoietic 
adult stem cells in the 1970ies, called MSCs, and pioneered the tremendous work on these 
adult stem cells till this day. As the name implies, these cells are derived from immature 
embryonic connective tissue, the mesenchyme. MSCs are fibroblast-like cells(70) that have a 
limited capacity for self-renewal(61) and exclusively possess multipotency, which means that 
they are primarily restricted to differentiate into cells of their origin, like chondrocytes, 
adipocytes and osteoblasts, but can also give rise to tendon, ligament, muscles, dermis and 
connective tissue(71). The potential to give rise to neuro-ectodermal cells, like neurons and 
astrocytes, and endodermal cell types, like hepatocytes, broadens the in vitro differentiation 
repertoire of MSCs tremendously(72-74). Although the majority of MSCs resides in the bone 
marrow, many studies report about the existence of MSCs in multiple organs and tissues in 
animals(75, 76) and humans(77), like adipose tissue, amniotic fluid, cultured pancreatic islets(78), 
periostium, fetal tissues(79) (i.e. aorta-gonad-mesonephros and yolk sac(80)), placental tissues, 
and others. This suggests a perpetual reservoir of tissue-specific stem cells in virtually all 
post-natal tissues for the regeneration of injured tissues and the replacement of damaged 
cells(81). The migration capacity towards inflamed tissues in response to chemotactic 
factors(82), has already been evaluated in pre-clinic studies via infusion of MSCs into animals 
and showed local engraftment in damaged tissues with repair potential to a greater or lesser 
extent in different disease settings(82, 83). Therefore, MSCs are believed to be the adult stem 
cell with highest therapeutic potential(84). 
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2.2.2 MSC markers 
MSCs are a very heterogeneous subset of stroma cells, expressing a great variety of 
markers, most of which are also present on multiple miscellaneous cell types. Due to the lack 
of specific antigens that clearly define MSCs, the “International Society for Cellular Therapy” 
postulated the minimal criteria to define MSCs(85), which facilitates a uniform phenotypic 
description. Beneath the potential to differentiate into osteoblasts, adipocytes and 
chondrocytes in vitro, MSCs must be plastic-adherent and have to express the membrane-
bound antigens CD73, CD90 and CD105. Further, the expression of CD11b or CD14, CD19 
or CD79, CD34 and CD45 should be absent(85). The lack of HLA-DR and the costimulatory 
molecules CD80 or CD86 renders MSCs as hypo-immunogenic cells, not able to induce 
allogeneic immune responses(86). 
2.2.2.1 CD73 
CD73, also known as Ecto-5’-nucleotidase (NT5E), dephosphorylates nucleotides, such as 
adenosinmonophosphate, thereby creating nucleosides(2, 87, 88), like adenosine. This 
glycophosphatidyl inositol (GPI)-linked dimer(1) is expressed on B and T cell subsets, like 
Tregs(89) and primed uncommitted Th cells
(90), endothelial cells, fibroblasts(91), germinal centre 
follicular DCs(1), epithelial cells(88) and MSCs from bone marrow(92) and other tissues. CD73 
seems to be implicated in the protection against tumor necrosis factor related apoptosis 
inducing ligand (TRAIL)-induced apoptosis(93) and might therefore be widely expressed on 
many tumor cell lines and cancerous tissues(94). 
2.2.2.2 CD90 
The thymocyte differentiation antigen-1 (Thy-1) or CD90, is a highly conserved GPI-anchored 
cell surface protein, which belongs to the immunoglobulin superfamily(1). Originally detected 
on thymocytes, CD90 is now widely used as a surrogate marker to identify and isolate 
immature CD34+ HSCs from peripheral blood(95), but also other stem cells, like keratinocyte 
stem cells(96) and MSCs. Further, this marker is expressed on T cells, neurons, activated 
endothelial cells(97, 98) and partly on fibroblasts(99, 100). It has been shown to be involved in the 
regulation of various nonimmunologic processes, as cell adhesion, tumor growth, migration 
and apoptosis(98). 
2.2.2.3 CD105 
The homodimer(1) CD105 or endoglin is mainly expressed on endothelial cells, especially in 
the vasculature of solid tumors, inflamed tissues and healing wounds(101). Further, it is 
present on activated monocytes, macrophages and bone marrow subsets(2), like MSCs(92). It 
is a component of the TGF- receptor complex(102) and capable to bind TGF- and modulate 
cellular responses to this growth factor(1). 
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2.2.2.4 CD271 
The low-affinity nerve growth factor receptor (LNGFR or CD271) is a specific marker for cells 
of the central and peripheral nervous system. Recently, it has been reported to be expressed 
on melanoma-initiating cells in humans(103), which started again the discussion, whether 
cancer stem cells may originate from the transformation of tissue-specific stem and 
progenitor cells. Formerly, the marker CD271 was described for the isolation of neural crest 
stem cells from peripheral nerves(104). Currently, it is a very promising candidate for the 
prospective isolation of high clonogenic MSC subsets from bone marrow(105, 106). Isolated 
CD271+ cells from bone marrow coexpress the well established MSC markers CD73 and 
CD105(106). 
2.2.2.5 CD56 
Beneath its expression on the surface of neurons, glial cells, skeletal muscle and 
neuromuscular junctions(88), the neural cell adhesion molecule (NCAM), or CD56, is 
expressed on virtually all resting and activated natural killer (NK) cells and subsets of B and 
T cells(1). The expression of CD56 in combination with the mesenchymal stem cell antigen-1 
and CD271 has been shown to define a distinct subtype of BM-MSCs, with distinct 
morphologic characteristics, a high clonogenic potential and enhanced differentiation 
capacity towards the chondrocyte lineage(107). 
2.2.3 Immunomodulatory potential of BM-MSCs 
The immunomodulatory properties of BM-MSCs have been demonstrated manifold in vitro 
and in vivo, but the mechanisms that drive this potential still remain elusive. Widespread in 
vitro studies have shown the hypo-immunogenic and profound immunosuppressive 
capacities of MSCs, through interactions with cells of the innate and adaptive immune 
system(108, 109). In vivo, MSCs are thought to maintain peripheral tolerance(110), regulate 
autoimmunity(111) and fetal-maternal tolerance(112) and might play a major role in tumor 
evasion(113). Further, autologous or syngeneic MSCs from bone marrow or blood(109) have 
been proven in clinical trials to be safe and partly reduce graft-versus-host disease and 
ameliorate the reconstitution of several patients hematopoietic system, when cotransplanted 
in HSC-therapies(114-116). Moreover, MSCs were demonstrated to have vigorous 
immunomodulatory activity on cells of the innate and adaptive immunity, including the 
inhibition of monocyte maturation and function(117) and the in vitro differentiation of CD34+ 
HSCs into DCs(118). Further, DC activity is down-regulated upon coculture with MSCs, 
regarding the expression of HLA-DR, costimulatory molecules and secretion of cytokines(119, 
120). The cytotoxic activity of NK cells, another important player of the innate immunity, was 
shown to be down-regulated through human MSCs in vitro(121). But also cells of the adaptive 
immunity are modulated by MSCs, including the suppression of B cell proliferation(122) and 
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differentiation into Ab-producing cells and affect their chemotactic properties(122). As B cell 
responses are mainly T cell-dependent, the effect of MSCs on T cells has accumulated major 
interest in the last years. MSCs have been reported to inhibit proliferation of CD4+ and CD8+ 
T cells stimulated with alloantigens, mitogens or specific Abs in vitro(123-125) and are able to 
induce peripheral T cell tolerance in mice models for autoimmunity diseases(126). This 
suppression is not obligatory the result of induced apoptosis(83), as T cell survival has been 
shown to be sustained in a quiescent state through MSCs, which leads to an overstimulation 
and subsequent activation-induced cell death(127). Further, it has been shown that BM-MSCs 
recruit, regulate(128) and stimulate the proliferation of CD4+ and CD8+ Tregs(129) and induce 
the differentiation of naive Th cells towards a regulatory phenotype
(130), with expression of 
FoxP3(131). The MSC-mediated immunomodulation is not solely cell contact dependent, as 
various soluble factors have been shown, to be, at least partly, implicated in the mechanism, 
like TGF-1, prostaglandine E2, IDO, human leukocyte antigen G5(109), inducible nitric oxide 
synthase, heme oxigenase 1(132) or cytokines such as IL-10(133). 
2.2.4 MSC niche 
The concept of a stem cell niche for HSCs was already introduced in 1978 by Schofield et 
al.(134) and has been supported from thereon, creating a new research field focussing on the 
in vivo identity and anatomic location of adult stem cells. BM-MSCs share their 
microenvironment with HSC and have been shown in murine studies to differentiate into cells 
producing the functional components that support hematopoiesis(135), like pericytes, 
myofibroblasts, stromal cells, osteoblasts and endothelial cells(83). Three types of niches have 
been described for HSCs(81), which are provided by cells originating from MSCs. The 
endosteal niche is formed by osteoblasts(136) in the trabecular area of the large bones, 
whereas the pericyte niche is composed of perivascular cells, which express alpha-smooth 
muscle actin (-SMA)(137). The third hypothesized niche is the vascular niche, which is built 
up by endothelial cells and CD146+ sub-endothelial stromal cells(83). However, stromal cells 
of every supposed niche provide the environment that prevents HSC differentiation, 
proliferation and apoptosis and maintains their self-renewal capacity(83) by keeping them in a 
quiescent state. Recently, Méndez-Ferrer et al. reported about a close association of MSCs 
and HSCs in rodent bone marrow. Nestin+ MSCs did not express vascular endothelial 
markers, like CD31 or CD34, but were distributed perivascular, mainly outside the endosteal 
region, which supports the theory of a perivascular niche(138). 
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2.3 Skin 
The skin, with a surficial area between 1.5-1.8 m2, is the largest sensory organ of the human 
body(139) and constitutes the first effective barrier against external physical, chemical or 
biological offenses(140). Schematically the skin structure is arranged in three main layers: 
(i) epidermis, including its specialized epithelial structures, namely the appendages, which is 
connected to the (ii) dermis or cutis by the dermal-epidermal basement membrane and the 
lowermost layer, which is called (iii) hypodermis or subcutis and anchors the skin to the deep 
fascia. 
2.3.1 Epidermis 
The superficial epidermis is a malpighian epithelium(140) that forms the first line of defense of 
the human body and has self-renewal capacities via proliferating resident stem cells(141, 142) 
that differentiate during their migration from the Stratum basale, through the Stratum 
spinosum, Stratum granulosum and Stratum lucidum to the Stratum corneum(143) (Fig. 2|). 
The epidermis originates from the ectoderm(140) and is non-vascularized, but contains many 
cutaneous appendages like hair and pilosebaceous follicles, sweat gland endings and 
nails(140, 144). The majority of epidermal cells is comprised of keratinocytes that are 
interspersed with professional APCs, called the Langerhans cells(143), which are specialized, 
mobile DCs. Another epidermal cell type, the melanocyte, is derived from the neural crest, 
produce the skin pigment melanin(140, 143) and can be found in the basal layer. Merkel cells(145) 
function as mechanotransducers(146) by contacting dermal sensory axons and are localized in 
the basal layer and around hair follicles(140). Lymphocytes are very infrequent in the 
epidermis and express mostly memory/effector T cell molecules(140, 147). 
2.3.2 Dermis 
The dermis can be separated into the papillary part underneath the epidermis that forms 
cones(140), which extend into the epidermis and provide additional stability, and the reticular 
or deep dermis. The main structural components that characterize this supportive, 
compressible and elastic connective tissue, are dermal fibres that are made of interstitial 
collagen and resist mechanical stress, elastic fibers that are responsible for the retractile 
characteristics(140) and the extrafibrillar matrix, which consists of proteoglycans and 
glycoproteins(140). The dermis is vascularized and nerved, contains vessels of the peripheral 
lymphatic system and the deep part of skin appendages(140). The fundamental cells of the 
dermis are the fibroblasts(143), which are the main producers of fibres and ground 
substance(140) and are also thought to have immunomodulatory functions(148, 149). Further, 
cells of the immune system, such as DCs (interstitial and plasmacytoid), mast cells, 
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macrophages, NK cells and T cells(147) (NKT cells, cytotoxic T cells and Th cells), can be 
found in low numbers in healthy human dermis(144, 150). 
2.3.3 Hypodermis 
The hypodermis - the innermost layer of the skin - connects the dermis to the fascia laying 
underneath and acts as energy reservoir via the fat storing adipocytes, which represent the 
main characteristic cell type(140). 
 
Fig. 2| Schematic overview of human skin. The outermost layer of the skin is built by A| the stratified 
epidermis, followed by B| the dermis and C| the subcutis. (Adopted from Gray
(151)
) 
2.3.4 Skin homing T cells 
Normal healthy skin harbors more than 2x1010 resident T cells(150) that are critical for 
cutaneous immunosurveilance(152) and are thought to play a major role in many inflammatory 
skin diseases, like psoriasis, atopic dermatitis or melanoma. The predominant T cell type in 
the epidermis expresses the markers CD8 and CD45RO, bears the common TCR(153)and 
is located in the basal and suprabasal layer of keratinocytes(150). In contrast, the dermis 
contains around 90% CD4- and only 10% CD8-positive cells(154), predominantly of a memory 
phenotype that mainly express, amongst others, a skin-homing receptor, called cutaneous 
lymphocyte antigen (CLA)(154), which is the ligand for E-selectin. Dermal T cells are located 
around postcapillary venules, close to the epidermal-dermal junction and in proximity to skin 
appendages(150). The vast majority of CD3+ T cells in fetal skin are naive CD4+ T cells, while 
only ~5% CD45RA+ T cells are found in adult non-inflamed skin under resting conditions(147). 
A 
B 
C 
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Among conventional T cells in human skin, like Th1, Th2 and Th17 cells, there exist also a 
small proportion of TCR cells and invariant NKT cells, which both have been reported to be 
involved in skin inflammatory diseases and cancer, but further studies are required to 
determine their specific functions(150). Approximately 5-10% of skin T cells express FoxP3 
and are able to suppress T cell proliferation in vitro(147). Both, epidermal Langerhans cells 
and dermal DCs, might be able to induce Tregs in the periphery, through production of 
TGF- and presentation of antigens via MHC II(15). Increased numbers of Tregs have been 
reported in cell carcinomas(155, 156) of the skin, primary melanoma and metastasizing forms of 
skin cancer. Interestingly, the majority of FoxP3+ Tregs from human peripheral blood bear 
skin-homing receptors, like CLA, the chemokine receptor CCR4 or CCR6(157). Further, 
leasonal skin of psoriatic patients contains Tregs with reduced suppressive capacity(158), 
which suggests a major role of Tregs in maintaining skin immune homeostasis(159). 
2.3.5 Skin-derived progenitor cells and their immunomodulatory potential 
Two types of progenitor cells have been described in human skin. Skin-derived precursor 
cells (SKPs) are neural crest-related progenitor cells identified in rodent(160) and human 
skin(161, 162), which posses multipotency and show remarkable self-renewing capacities. SKPs 
are isolated by culturing of dissociated skin with epidermal and fibroblast growth factors, 
which results in the formation of spheres that can be transferred into new culture flasks and 
subsequently expanded(160), while remaining their differentiation capacities(162). SKPs express 
markers specific of embryonic neural crest(163) and Nestin+ cells were shown to differentiate in 
vitro into neural cell types, expressing neuronal markers like -III-tubulin, neurofilament-M, 
neuron-specific enolase and markers specific for the peripheral nervous system, like 
CD271(164) and CD56. Also glial markers, like the glial fibrillary acidic protein (GFAP) and 
CNPase could be detected, but resulted from differentiation of distinct SKP 
subpopulations(160). Additional clonal analysis of diverse SKPs identified the individual 
potential of different clones to differentiate into neuronal and glial cells, but also into cells of 
the mesenchymal lineage, like -SMA-expressing cells or adipocytes. SKPs were found to 
be situated in a distinct dermal niche, within the hair papillae(165) and whisker follicles(163). This 
distincts SKPs from dermis-derived MSCs that are predominantly isolated from glabrous 
skin, like foreskin(161). These progenitor cells might occupy a perivascular niche, known 
already from BM-MSCs, or reside in the interfollicular dermis(166) and can be isolated via 
sphere formation(161), described above, or removal of the epidermis, subsequent enzymatic 
digestion of apical dermis and selection for plastic adherence(148, 167). MSC-like cells were 
described to be present in variable numbers within different skin donors(167) as just some 
cells within the dermal cell pool were able to differentiate into adipocytes, osteoblasts and 
chrondrocytes(167). Further, dermal MSCs have been reported to differentiate in vitro into 
neurons, glia, smooth muscle cells and cells of the peripheral nervous system as well(161). 
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Investigations of the immunomodulatory potential revealed that dermal MSCs are functionally 
comparable to BM-MSCs(148), for instance they are capable to restore the microenvironment 
in bone marrow, through the maintenance HSC proliferation, engraftment and survival in 
vivo, at least in animals(168). Further, human dermal MSCs have been reported to induce DC 
maturation(149), to suppress the proliferation of allogeneic T cells and PBMCs(167) in vitro via 
similar mechanisms, although reversible, modulate the cytokine expression pattern of T cells 
(148), cause cell-cycle arrest in PBMCs(167) and prevent apoptosis. Additional in vitro models of 
human graft-versus-host disease showed that after exposure of T cells with dermal MSCs, 
the reactions were at least dampened slightly(148). This enhances the idea of an alternative 
MSC source that is easily accessible and could be used for cellular therapies. 
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3 Objective of the thesis 
Mesenchymal stem cells are a very heterogeneous population of adult stem cells, resident in 
various tissues. We have previously shown that the human dermis harbors different MSC 
subsets. To better understand the localization and potential role of tissue-resident MSCs for 
the maintenance of skin immune homeostasis, it was the aim of this thesis to: 
i) localize dermal MSCs via immunofluorescence and to allocate them into a dermal MSC-
niche in situ, through analysis of the microenvironment 
ii) visualize the morphology of adherent dermal cells in vitro via immunofluorescence 
iii) investigate the immunosuppressive potential of dermal MSC subsets via coculture 
assays with T cells and naive helper T cells and to elucidate the mechanism(s) that drive 
this immunosuppression 
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4 Materials & Methods 
4.1 Apparatuses, instruments and software 
1450 Microbeta liquid scintillation counter PerkinElmer, Waltham, MA, USA 
Cell separator (MiniMACS) Miltenyi Biotech, Bergisch-Gladbach, GER 
Centrifuge 5415 R Eppendorf, Hamburg, GER 
Compound microscope (Eclipse 80) Nikon, Tokyo, JP 
Confocal laser scanning microscope 510 Zeiss, Jena, GER 
CO2 incubator, humified Heraeus, Vienna, AUT 
Cooling centrifuges Heraeus 
Counting chamber Neubauer improved, Laboroptik, GER 
Cryo 1°C freezing container „Mr. Frosty“ Nalgene/NUNC, Rochester, NY, USA 
EasySep® Stemcell Technologies, Grenoble, F 
FloJo Software Tree Star Inc., Ashland, OR, USA 
Flow cytometer (LSR II) Becton Dickinson, San Jose, CA, USA 
Forceps  
Freezers (-20°C, -80°C)  
Fridges  
Irradiator IBL 437C CIS bio international, Gif sur Yvette, FR 
JungCM1800 Cryostat Leica Microsystems, Wetzlar, GER 
Laminar flow Holten, Allerod, DK 
LSM image browser Zeiss 
Microcentrifuges Eppendorf 
Nikon Coolpix 995 digital camera Nikon, Tokyo, JP 
Optical microscope Nikon eclipse 80i Nikon 
Pipet Gilson, Middleton, MI, USA 
Pipetman (1-50 ml) Hirschmann, Eberstadt, GER 
Prism 5 for Windows GraphPad Software, Inc., La Jolla, CA, USA 
Scale Sartorius, Vienna, AUT 
Scalpels  
Scissors  
Stainless steel metal mesh  
Vortex Genie 2 Lactan, Graz, AUT 
Water bath GFL, Burgwedel, GER 
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4.2 Consumables 
Bottle-top filters (0.2 and 0.4 µm) Cornig, Amsterdam, NL 
Cell separation columns (MS, LS) Miltenyi Biotech 
Cell strainer (40 and 70 µm) Falcon, Lincoln Park, New Jersey, USA 
Culture flasks Cornig 
Eppendorf tubes (1.5 ml, 2 ml) Eppendorf 
Falcon tubes (15 ml, 50 ml) Becton Dickinson Bioscience 
Gloves Sempermed, Vienna, AUT 
Lab-Tek™ II – CC2™ chamber slide™(8-well) Nalgene/NUNC 
Microscope glass cover slips (24x40mm) Marienfeld, Lauda-Königshofen, GER 
Microscope slides Marienfeld 
Microtubes for flow cytometry Micronic, Lelystad, NL 
Parafilm Brand, Wertheim, GER 
Petri dishes for tissue culture (100x20mm) Cornig 
Pipettes (2 ml, 5 ml, 10 ml, 25 ml, 50 ml) Cornig 
REAL™ capillary gap microscope slides Dako, Glostrup, DK 
Round-bottom 96-well-plates Cornig 
Sterile tips (1-100 and 200-1000µl) Cornig 
4.3 Chemicals, reagents, buffers and media 
3-isobutyl-1-methylxanthine Sigma-Aldrich, St. Louis, MO, USA 
7-AAD Sigma-Aldrich 
Acetone (p.a.) Merck 
Alizarin Red Sigma-Aldrich 
Alpha-MEM Gibco, Invitrogen, Carlsbad, CA, USA 
Ascorbic acid Sigma-Aldrich 
Antibodies see Table 4| 
Betaisodona Mundipharma, Vienna, AUT 
-mercaptoethanol Gibco 
BSA Sigma-Aldrich 
CFSE Molecular probes, Eugene, Oregon, USA 
Cytofix/Cytoperm solution Becton Dickinson Bioscience 
Dexamethasone Sigma-Aldrich 
Dispase II (neutral protease, grade II) Roche Applied Science, Basel, CH 
DMEM Gibco 
DMSO Serva, Heidelberg, GER 
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Dynabeads Invitrogen 
Elite mouse IgG Vectastain Kit Vector Laboratories, Burlinghame, CA, USA 
FACS Sheath Becton Dickinson Bioscience 
Fetal calf serum (heat-inactivated) PromoCell, Heidelberg, GER 
FicollHypaquePLUS Amersham Bioscience, Buckinghamshire, UK 
Gentamicin PAA, Pasching AUT 
Giemsa’s Azure Eosin Methylene Blue Merck 
Glycerol-2-phosphate Sigma-Aldrich 
[3H]-Thymidine Hartmann Analytic, Göttingen, GER 
Hematoxiline monohydrate Merck 
Heparin Biochrom AG, Berlin, GER 
HPL Dr. Dirk Strunk, Med. Univ. of Graz, AUT 
Hydrogen peroxide (30%) Merck, Darmstadt, GER 
Indomethacine Sigma-Aldrich 
Insulin (human) Sigma-Aldrich 
Isopropanol Merck 
L-glutamine Gibco 
Liberase Blendzyme 3 Roche Applied Science 
May-Grünwald’s eosin methylene blue sol. Merck 
MEM Alpha Medium + Glutamase – I (1x) Invitrogen 
Methanol Merck 
Microbeads (anti-biotin, -PE, -APC) Miltenyi Biotec 
Mounting medium for immunofluorescence Vector Laboratories 
Mounting medium for immunohistochemistry Aquatex, Merck, Darmstadt, GER 
Non-essential amino acids Gibco 
O.C.T. Tissue-Tek, Sakura Finetek, Zoeterwoude, NL 
PBS Gibco 
PenStrep Gibco 
PFA Merck 
RPMI 1640 Gibco 
Saponin Sigma-Aldrich 
Sodium pyruvate Gibco 
Trypan blue (0.4%) Sigma-Aldrich 
Trypsin-EDTA solution Gibco 
(1x; 0.05% Trypsin, 1 mM EDTA) 
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4.4 Buffers and solutions 
4.4.1 Magnetic cell sorting (MACS) buffer 
1x PBS 
2 mM EDTA (for cell culture, autoclaved) 
0.5% BSA 
 
4.4.2 Dynabead buffer 
1x PBS 
0.1% BSA 
2 mM EDTA (pH 7.4) 
 
4.4.3 Buffers, fixatives and Ab diluents for immunofluorescence (IF) and 
immunohistochemistry (IHC) 
Wash buffer for IF and IHC staining (1x) 
10x PBS 
aqua bidest 
 
Ab diluent (2% BSA-PBS) 
1x PBS 
BSA (v/v 2%) 
 
4.4.4 Buffers for flow cytometry 
FACS buffer (FACS-Flow + 1% FCS) 
For one liter of FACS buffer a sterile bottle was filled up with FACS-Flow and heat-
inactivated FCS (see section culture media) was added in the appropriate amount to get a 
1% concentration of FCS in the whole volume. 
FACS washing buffer I (1x PBS + 5% FCS) 
For each staining the buffer solution was freshly prepared [can be stored at 4°C for a 
maximum of 1 week, otherwise conservatives (acid) have to be added]. 
 
FACS permeabilisation buffer (1x PBS + 0.1% saponin) 
The permeabilisation buffer was either freshly prepared (can be stored for up to one week), 
or a higher concentrated stock solution (10% saponin) was made that can be stored longer, 
and diluted to the adequate concentration before usage. 
 
FACS washing buffer II (1x PBS + 0.1% saponin + 5% FCS) 
FCS was added in the adequate concentration to the permeabilisation buffer. 
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4.4.5 Paraformaldehyde (PFA) 
The 8% stock solution was stored at -20°C. The fixation reagent was diluted with 1x PBS to 
get a 4% solution. This was stored for up to 2 weeks in the fridge. 
 
4.4.6 Carboxyfluorescein succinimidyl ester (CFSE) stock-solution 
First, a stock solution was prepared with DMSO to get a final concentration of 5 µM (molar 
mass of CFSE = 557.47g/mol). Aliquots of 100 µl were stored at -20°C for several months. 
4.5 Cell culture media 
All media were always freshly prepared. 
4.5.1 Heat inactivation of FCS 
Frozen FCS was thawed o/n at 4°C and subsequently heat inactivated (56°C for 30 min) in a 
prewarmed waterbath. The serum was left to cool down for 30 min and 50 ml aliquots were 
prepared and immediately stored at -20°C. 
4.5.2 NCM (Normal conditioned medium) 
500 ml RPMI 1640 
10% FCS 
10 µg/ml gentamycin 
2 mM L-glutamine 
0.1 mM non-essential amino acids 
1 mM sodium pyruvate 
50 M -mercaptoethanol, 1% PenStrep 
 
4.5.3 -MEMDERM 
500 ml MEM Alpha 
10% FCS 
1% PenStrep 
 
4.5.4 -MEMBM 
500 ml MEM Alpha 
10% FCS 
 
4.5.5 Expansion mediumBM 
For expansion of bone marrow-derived cells, we used human platelet lysate (HPL) instead of 
FCS, as it has been reported by Schallmoser et al.(169) that the mean population doublings 
are significantly higher, which means that they expand more rapidly with addition of HPL. 
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Aliquots of 50 ml were centrifuged at 3000 rpm and the supernatant (around 40 ml) was used 
as supplement. 
 
500 ml MEM Alpha 
8-10% HPL 
2 IU/ml Heparin 
 
4.5.6 HaCaT & HEK 293 medium 
500 ml DMEM 
10 % FCS 
1 % Penicillin/Streptomycin 
 
4.5.7 AdipoIND medium 
-MEMDERM 
0.2 mM indomethacine 
1 µM dexamethasone 
0.5 mM 3-isobutyl-1-methylxanthine 
10 µg/ml recombinant human insulin 
 
4.5.8 OsteoIND medium 
-MEMDERM 
1 µM dexamethasone 
50 µg/ml ascorbic acid 
10 mM glycerol 2-phosphate 
4.6 Kits 
4.6.1 Pan T cell isolation kit II 
Biotin-conjugated mAbs against CD14, CD16, CD19, CD36, CD56, CD123, and 
CD235a/Glycophorin A. Microbeads conjugated to a monoclonal anti-biotin Ab (isotype: 
mouse IgG1; Miltenyi Biotec). 
4.6.2 Naive T cell isolation kit  
Biotin-conjugated mAbs against CD8, CD14, CD15, CD16, CD19, CD25, CD34, CD36, 
CD45RO, CD56, CD123, TCR, HLA-DR, and CD235a. Microbeads conjugated to a 
monoclonal anti-biotin Ab (isotype: mouse IgG1; Miltenyi Biotec). 
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4.7 Isolation of dermal cells 
Non-inflamed juvenile human foreskin, undergoing routine circumcision, was obtained as 
discarded material. The study was approved by the ethics committee of the Medical 
University of Vienna in accordance with the Declaration of Helsinki Principles and parents 
gave their written informed consent. Until further processing, skin was stored (4°C in 1x PBS) 
for a maximum of 24 hours. The subcutis was scraped off with a sterile scalpel, before the 
skin was incubated for 5-10 min in undiluted Betaisodona at RT. Excess Betaisodona was 
flushed away with 70% ethanol. The disinfected skin was rinsed with 1x PBS and cut 
immediately into small pieces (4x2 mm), which were placed dermal side down on a 
25% dispase solution (in 1x PBS) and incubated o/n at 4°C. On the next day, the epidermis 
was separated manually from the dermis with two forceps. The dermis was sheared with a 
scalpel and incubated for 90 min in 2x Liberase (equals 9.88 Wünsch units) + 10 ml 1x PBS 
(total collagenase concentration in dissociation solution: 0.18 mg/ml) at 37°C in a waterbath, 
shaken constantly to digest the tissue. To obtain single cells, the suspension was first sieved 
through a steel mesh to get rid of the undigested parts and thereupon filtered through a 
70 µm cell strainer. Cells were washed with 30 ml NCM and centrifuged at 1400 rpm for 7 
min at RT to collect the cells. The pellet was resuspended in medium and stored at 4°C until 
further processing. 
4.8 Isolation of peripheral blood mononuclear cells (PBMCs) 
Human PBMCs were isolated from purchased buffy coats of healthy adult volunteers that 
donated blood at the local transfusion service (Rotes Kreuz, Vienna, AUT). 
4.8.1 Ficoll-PaquePLUS density gradient centrifugation for isolating PBMCs 
1.) Bring all involved reagents at RT. 
2.) Blood samples are taken into heparinized tubes (Vacuette, 9 ml draw capacity). 
3.) Invert the tubes several times to avoid coaggulation. 
4.) Transfer the blood into 50 ml Falcon tubes and dilute 1:1 with 1x PBS. 
5.) Add 9 ml of Ficoll-Paque PLUS (specific density 1.077 g/ml) by pipeting it slowly under 
the PBS-blood-mixture. 
6.) Centrifuge for 25 min at 1300 rcf without brake. 
7.) Pipett off the cloudy interface, which contains the mononuclear cells. 
8.) Wash for at least 2 times with 1x PBS or NCM before follow up experiments. 
4.9 Cell separation with MACS® 
In general this cell separation technology is based on the detection of cell surface molecules 
by Abs, which are either covalently linked to a superparamagnetic nanoparticle(170) (direct 
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labeling) or function as primary Abs that are unconjugated, biotinylated or fluorochrome-
conjugated. When using the indirect labeling method, the magnetic labeling is performed in a 
second-step procedure by using anti-immunoglobulin, anti-biotin, streptavidin or anti-
fluorochrome microbeads. By placing the column into the separator, a high-gradient 
magnetic field is induced in the column matrix, which retains labeled cells with a high 
efficiency (positive selection). In case that untouched cells are needed, a mix of Abs can 
label all redundant cells and retard them in the column, while the desired fraction can pass 
unhampered (negative selection, see following section). 
For cell separation, different isolation strategies were used. To enrich dermal subpopulations 
positive selection with direct magnetic labeling or via biotinylated Ab was used. The enriched 
cell suspension was called “positive fraction”, or CDxy+, the flow-through cells were termed 
“negative fraction” (or CDxy-). CD3+CD4+CD25RA+CD25- cells were isolated by initial 
depletion of CD25+ cells, followed by the usage of the isolation kit for naive Th cells, where 
untouched cell suspensions could be obtained. In brief, CD25+ cells were labeled indirectly 
with an anti-CD25-mAb that was covalently linked to the fluorochrome APC. Anti-APC 
microbeads targeted the labeled cells for retention in the column. The flow-through cells were 
termed “CD25 negative” (CD25-) and used for the subsequent isolation of untouched naive 
Th cells. 
4.9.1 Depletion of CD25+ cells 
Ice-cold MACS buffer was used and working steps were performed as fast as possible. 
1.) Resuspend PBMCs in 1 ml of MACS buffer. 
2.) Take approximately 10 µl for flow cytometry. 
3.) Add 20 µl of Ab per 1x108 cells and mix well. 
4.) Incubate at 4°C for 30 min. 
5.) Wash with MACS Buffer ( 6 min, 1400 rpm). 
6.) Resuspend pellet in 500µl MACS buffer. 
7.) Add the microbeads (at least twice the amount of the Ab). 
8.) Incubate for 20 min at 4°C. 
9.) Wash with MACS buffer. 
10.) Resuspend in 2 ml of buffer and put the cell suspension on the washed column. 
11.) Collect the CD25- fraction for further enrichment. 
12.) Elute the CD25+ cells with 2 ml MACS buffer. 
13.) Keep from every fraction at least 10µl for purity control by flow cytometry. 
14.) Wash the cell suspension with 1x PBS or NCM and keep cool until further handling. 
4.9.2 Enrichment of untouched naive Th cells 
The protocol was adapted from Miltenyi Biotec 
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1.) Wash cells with MACS buffer. 
2.)  5 min, 1400 rpm. 
3.) Discard supernatant and resuspend the pellet with 1 ml MACS buffer. 
4.) Determine cell number with trypan blue. 
5.) Wash again with MACS buffer (5-10 ml;  5 min, 1400 rpm). 
6.) Take 10-20 µl for flow cytometry analysis. 
7.) Cell number  1x107   40 µl MACS buffer 
  1x107   70 µl MACS buffer 
8.) Add 10 µl of the Ab cocktail per 1x107 cells and incubate for 10 min at 4°C in the dark. 
9.) Add 40 µl MACS buffer and 20 µl anti-biotin microbeads for 1x107 cells and incubate 
(4°C, 20 min) 
10.) Wash cells with 5-10 ml MACS buffer. 
11.) Place the appropriate column in the magnetic field of the according separator (see 
Table 2|) and wet the column with 1 ml MACS buffer. 
12.) Resuspend the pellet in 500 µl buffer and apply cell suspension onto the column. 
13.) Collect flow-through cells, containing unlabeled naive Th cells. 
14.) Elute the negative fraction with 1 ml MACS buffer. 
15.) Take from every fraction aliquots for flow cytometric examination of purity. 
16.) Wash cells with 1x PBS or NCM and use immediately for downstream applications or 
refrigerate (for a maximum of 2 hours) 
Table 2| Parameters for cell separation column decision 
 
Column 
Max. number of 
labeled cells 
Max. number of 
total cells 
 
Separator 
MS 10
7
 2x10
8
 MiniMACS 
LS 10
8
 2x10
9
 MidiMACS 
(adopted from Miltenyi Biotec) 
4.9.3 Positive selection of dermal subpopulations expressing MSC markers 
1.) Wash the freshly prepared single cell solution with MACS buffer ( 7 min, 1400 rpm). 
2.) Resuspend in 1 ml MACS buffer and add the appropriate volume of Ab (see Table 3|) 
3.) Gently resuspend several times and incubate at 4°C for 45 min. 
4.) Wash with 5 ml MACS buffer ( 5 min, 1400 rpm). 
5.) Resuspend the pellet in 100 µl MACS buffer. 
6.) Add 50 µl anti-PE, anti-APC or anti-biotin microbeads and incubate for 15 min at 4°C. 
7.) Wash with MACS buffer ( 5 min, 1400 rpm) 
8.) Resuspend the pellet in 500 µl MACS buffer. 
9.) Place a MS column in the separator and wash it with 500 µl buffer before loading the cell 
suspension. 
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10.) Collect the flow-through and combine it with the retarded positive fraction by elution with 
1 ml of MACS buffer. 
11.) Proceed once again as stated in point 9.) with a new column. 
12.) Collect the flow-through, which we call “negative fraction” (CDxy-)a 
13.) Wash the column 2 times with buffer. 
14.) Elute the “positive fraction” (CDxy+) with 1 ml MACS buffer. 
15.) Take from every fraction 5-10 µl for flow cytometry analysis of purity. 
16.) Wash both fractions and whole dermal cells with medium and store them at 4°C unless 
otherwise processed. 
Table 3| Abs and dilutions for enrichment of dermal subtypes 
Ab 
specifity 
 
Clone 
 
Ig Class 
Working 
dilution 
 
Source 
 
Conjugate 
CD271 ME20.4-1.H4 mouse IgG1 1:20 Miltenyi, BD APC, Biotin 
CD73 AD2 mouse IgG1 1:20 BD PE 
CD90 5E10 mouse IgG1 1:20 BD PE 
4.10 Expansion and culture of plastic-adherent bone marrow cells, 
umbilical cord blood cells and dermal cells 
Cryopreserved, unpassaged adherent bone marrow cells from a healthy adult male volunteer 
and umbilical cord blood cells (a kind gift from PD Dr.med. Dirk Strunk, Div. of Hematology, 
Medical University of Graz) were quickly thawed at 37°C and washed immediately with 50 ml 
NCM ( 7 min, 1,400 rpm). The pellet was resuspended in expansion medium, cells were 
plated in 4 vented culture flasks (2.5x105 cells/225 cm3) and expanded for 8-12 days in a 
humified atmosphere containing 95% air and 5% CO2. Medium was changed every 2-3 days. 
When almost confluent, the medium was aspirated off and the cell layer was washed gently 
with prewarmed 1x PBS. Cells were harvested by detaching them with prewarmed trypsin-
EDTA for 3-4 min at 37°C (frequently controlled under the microscope), flushing them down 
the culture flask by repeated pipetting 5-10 ml of NCM over the plastic surface and collecting 
by centrifuging. The pellet was resuspended in culture medium, counted and frozen in 
aliquots (1st passage). For in vitro experiments these aliquots were thawed as described 
before and cultured under normal conditions with -MEMBM. 
Dermal cells were expanded and maintained in -MEMDERM at 37°C and 5% CO2. For 
expansion, cells were plated at a density of 1.5x104 viable cells/cm2 in plastic petri dishes 
(id = 9 cm) for 5-10 days, with medium changed every 2-3 days. Once 80-90% confluency 
was reached, cells were trypsinized, as described above, and stored in aliquots in liquid 
nitrogen for future experiments. 
                                                 
a
 Although called “negative fraction”, a varying percentage of cells expressing the “depletion antigen” was still 
present (5-40%, depending on the marker). 
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For analysis of phenotypical and morphological appearance of dermal and bone marrow 
cells, they were cultured in 8-well chamber slides (2-3x104 cells/cm2) in their respective 
culture medium (250 µl/well). After 1-2 days, cells were about 80% confluent and ready for 
immunohistochemistry or visualization by immunofluorescence. 
As bone marrow cells were found to be plastic-adherent, expressed all markers necessary 
for defining MSCs and showed the potential to differentiate into the three main mesenchymal 
lineages (chondro-, adipocytes, osteoblast), which was shown by C. Vaculik from our 
laboratory, they were termed BM-MSCs in upcoming experiments. 
4.11 Expansion and culture of HaCaT and HEK 293 cells 
Cryopreserved HaCaTb and HEK 293c were quickly thawed at 37°C and transferred into 
225 cm3 culture flasks with 30 ml of HaCaT & HEK 293 medium and left to adhere o/n. On 
the next day, medium was changed and cells were expanded for up to 2 weeks with medium 
changed every 2-3 days. When cells were around 80% confluent, cells were splitted 1:2 for 
HaCaT or 1:3 for HEK 293 by detaching them with trypsin-EDTA (0.5%) as described above. 
After sufficient expansion, cells were detached, one part used for experiments and the other 
part frozen and stored in liquid nitrogen (see 4.13). 
4.12 Cell counting 
The cell pellet was resuspended in the appropriate medium (volume according to pellet size), 
10 µl were mixed with an equal volume of 0.1% trypan blue (in 1x PBS) and incubated for 
several min at RT. Stained cells (10 µl) were loaded into a counting chamber (Fig 3|), viable 
cells were counted in all four quadrants (grey) and the concentration was calculated 
according the following principle: 
Formula: 
 
 
 
 
 
Fig. 3| Quadrants of 
counting chamber 
                                                 
b „Human adult low Calcium high Temperature keratinocytes“; HaCaT are a permanent human epithelial cell line, 
originated from the periphery of a primary malign melanoma of the upper back skin of a male patient
(171, 172)
. 
c
 “Human Embryonic Kidney” cells; a human cell line that was originally transformed with adenovirus type 5 DNA 
fragments
(173)
. 
counted cell number 
 
enumerated area (mm
2
) x depth of chamber (mm) 
x dilution 
 
=  cells per µl 
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4.13 Cryopreservation of dermal and bone marrow cells 
The cell number of freshly prepared or expanded cells was estimated as described above 
and the concentration was adjusted to 1x106 cells/ml with the appropriate culture medium. 
Aliquots of 900 µl were pipetted into cryopreservation vials, mixed with 100 µl DMSO (10% 
v/v) and placed immediately into an isopropanol bath (freezing container that cools 1°C/min) 
that was subsequently cooled in a -80°C freezer. In case, the freezing container was not 
available, the vials were placed into a polystyrene rack, which was put into a polystyrene box 
and thereupon deep frozen at -80°C. Within the next few days, the cells were transferred into 
the liquid nitrogen tank for final storage. 
4.14 Chamber slides 
At about 80% confluency of dermal and bone marrow cells, the medium was discarded and 
media chambers were detached from the glass slide via the separator (Fig. 4|). The slides 
were washed in 1x PBS for a few min and cells were fixed and permeabilized with methanol 
absolute for 5 min at RT. After rehydration in 1x PBS and drying of the spaces between the 
culture-wells with cotton swabs (Fig. 4|, white arrow), cells were covered with Ab solutions 
for visualization assays (see 4.16). 
 
 
Fig. 4| Chamber slides with gasket removal supply. We used 8-well 
chamber slides to culture and directly stain isolated single cells. The 
picture illustrates the removal of the media chambers that allows 
subsequent fixation and direct staining of adherent cells on the 
remaining microscope slide. The arrow depicts the gaps between the 
culture chambers. (picture adopted from Nalgene/NUNC
(174)
) 
 
4.15 Preparation of skin cryosections 
After excision of the subcutis, skin was cut into small pieces (~ 3x10 mm) and embedded in 
O.C.T tissue-tec. These specimens were snap-frozen in liquid nitrogen and stored short time 
at -20°C or for longer periods at -80°C. For sectioning, blocks were affixed to the designated 
device on the cryostat, sections (5-7µm) were cut and adhered on capillary gap microscope 
slides, air-dried and fixed for 10 min in ice-cold acetone (-20°C). Slides were either used 
immediately or stored for future experiments. Before staining procedures, excess tissue-tec 
was scraped off and sections were encircled with a delimiting pen that provides a water 
repellent barrier for liquids. Before incubation with mAbs, the sections were rehydrated a few 
min in 1x PBS. 
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4.16 Immunofluorescence 
Skin cryosections or single cells fixed on chamber slides, were incubated for 2 hours at RT or 
o/n at 4°C with primary mAbs in a humified staining box in the dark. MAbs were diluted in 
2% BSA-PBS according to Table 4|, 50 µl were added to cells and/or tissues. For single 
staining with direct-conjugated mAbs, slides were washed three times in 1x PBS (in the dark) 
after the incubation step and mounted with a 1:6 dilution of Vectashield with DAPI (to 
visualize nuclei) and straight Vectashield mounting medium for fluorescence. Purified mAbs 
and those, who emitted only low intensity signals due to low marker expression on cells, 
were incubated at RT for up to one hour with a second-step (detecting/enhancing) Ab (AF488, 
AF546, AF647), following the primary incubation and washing steps. In this case, a blocking 
step had to be included for double and triple staining, if the primary, secondary or tertiary 
mAb derived from the same species (like mouse anti-human). This was performed with 10% 
normal mouse serum (diluted in 1x PBS) or 10% normal goat serum for 30-60 min at RT. 
After blocking, the secondary and/or tertiary mAbs were pipetted onto the skin sections or 
cells without an additional washing step in-between and incubated for 2 hours at RT or o/n at 
4°C. Afterwards, the slides were washed 3 times for 5 min and mounted with a DAPI-dilution. 
Isotype-matched controls from the same subclass, species and fluorochrome were treated 
exactly the same way like the specific mAbs. Pictures were captured with a confocal laser 
scanning microscope (CLSM) or a compound microscope (Nikon). 
4.17 Immunohistochemistry 
Primary mAbs and isotype-matched controls were diluted with 2% BSA-PBS according to the 
specifications in Table 4|. Fifty µl were pipetted onto the skin sections and incubated o/n at 
4°C in a moisture chamber. The next day, slides were washed at least 2 times with 1x PBS 
for 5 min, incubated for 10 min with 1% hydrogen peroxide (30% H2O2 diluted in MetOH abs.) 
at RT to quench the endogenous peroxidase, washed again in 1x PBS and incubated for 1 
hour at RT with the detecting second-step reagent that is covalently linked to a horseradish 
peroxidase. After an additional washing step, one drop of the substrate chromogen (AEC+) 
was placed on the section, which is metabolized in an enzymatic reaction into a red end 
product. The sections were mounted with an aqueous mounting solution (Aqua-mount). For 
enhancement of this staining procedure an intermediate step was included, to amplify the 
signal. A biotinylated IgG and IgM goat anti-mouse Ab was used for detection of the primary 
mouse anti-human mAb and incubated for 1 hour at RT. Meanwhile 20 µl of each, solution A 
and B (from the Vectastain-Kit for IHC), were mixed, diluted with 1.25 ml of 2% BSA-PBS 
and incubated for 45 min in the dark at RT. The slides were washed 2 times for 5 min in 1x 
PBS, 50 µl of the complex-solution was pipetted onto the sections and incubated for 45 min 
at RT in a humified box. After 2 washing steps, the chromogen solution was dropped onto 
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the slides and the production of the colorimetric end product was controlled under an 
inverted light microscope. After washing, the nuclei were stained with pure hematoxilin for a 
maximum of 1 min when indicated, the slides were washed again and mounted with Aqua-
mount. Pictures were captured and analyzed with a compound microscope. 
4.18 Dermal sheets 
Subcutis from foreskin was gently scraped off with a scalpel. Then the skin was cut 
(~ 2x10 mm rectangles) and placed dermal side down on 3.8% ammoniumthiocyanate (in 
1x PBS) for 1 hour at RT. The epidermis was separated from the dermis with 2 forceps and 
discarded, while the dermis was washed in 1x PBS for several min. To enhance the 
effectivity of the fixation, the tissue was cut into smaller pieces and thereafter incubated for 
30 min in 2% PFA at RT. The fixed sheets were washed for 5 min in 1x PBS, incubated for 
10 min in 2% BSA-PBS and placed into an Eppendorf tube containing the primary Ab in 100 
µl BSA-PBS, o/n at 4°C. On the next day, sheets were washed 3 times for 5 min in 1x PBS, 
spread on a microscope slide and mounted with Vectastain for immunofluorescence. 
Specifity was confirmed with isotype-matched control mAbs and the dermal sheets were 
captured and analyzed with a CLSM. 
4.19 Adipogenesis assay 
To test the differentiation capacity of bone marrow and dermal cells into adipocytes, cells 
(1x104/500 µl) were seeded into 48-well plates and cultured for approximately one week with 
-MEMDERM until confluency was reached. To differentiate the cells, AdipoIND medium was 
added to the cell layer and the induction medium was exchanged every 2-3 days for a total of 
3 weeks. To visualize adipocytes, medium was discarded and cells were fixed with 4% PFA 
for 45 min at RT. Thereafter, cells were washed 3 times for 5 min with 1x PBS and 2 times 
with aqua bidest. The Oil Red O stock solution (3 mg/ml in isopropanol) was diluted 3:2 in 
aqua bidest, filtered and fixed cells were overlaid with the solution for 50 min at RT. 
Afterwards, the cells were washed for 3-4 times with aqua bidest to remove the staining 
solution, covered with water and stored at 4°C until analysis with a compound microscope. 
4.20 Osteogenesis assay 
To evaluate the differentiation capacity of dermal cells into osteoblasts, dermal cells 
(4x103cells/250µl) were cultivated in chamber slides. After 2 days, dead cells and debris 
were removed by aspiration of the medium, fresh culture medium (-MEMDERM) was added 
and the adherent cells were cultured for another 2 days, before the differentiation was 
initiated with freshly prepared OsteoIND medium. Every 2-3 days the complete medium was 
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changed for 3 weeks in total. The negative control was cultured in -MEMDERM. Osteogenesis 
was detected by staining calcific depositions in cells with Alizarin Red. In brief, the medium 
was discarded, cells were fixed for 5 min with 4% formalin in 70% EtOH (v:v = 1:1, mixed at 
4°C) at RT, afterwards incubated with an Alizarin Red solution for 10 min at RT and gently 
washed in tap water until excess dye was removed. The slides were dried and pictures were 
captured with a compound microscope. 
4.21 Differentiation potential of cryopreserved, plastic-adherent 
dermal cells 
The multilineage differentiation potential is an important criterion to characterize MSCs. 
Christine Vaculik from our laboratory showed that freshly isolated dermal cells can 
differentiate into the three main lineages, namely adipocytes, osteoblasts and chondrocytes 
(manuscript in preparation). As cells can be altered by cryopreservation and storage for 
longer periods in liquid nitrogen, we tested the differentiation capacity of cryopreserved 
plastic-adherent total dermal cells into osteocalcin-producing or fat droplet-containing cells. 
In brief, cells were thawed and cultured for 21 days with supplemented media to induce the 
differentiation from uncommitted cells into osteoblasts or adipocytes that were stained with 
alizarin red and Oil Red O, respectively. Indeed, we found strong staining of calcific 
depositions throughout the culture (Fig. 5| A|, left), whereas staining was not observed in 
undifferentiated cells, which served as negative controls (Fig. 5| A|, right). Within the 
uniform alizarin red staining strong calcified nodules can be seen, that appear dark red 
(arrows). Single cells of plastic-adherent dermal cells showed the potential to build fat 
depositions upon induction (Fig. 5| B|, left). As cryopreservation does not interfere with the 
differentiation capacity of plastic-adherent dermal cells and it was shown for BM-MSCs that 
freezing does not affect the functionality(175), it can be assumed that the cells can be stably 
stored without loss of function. 
- 42 - 
 
Fig. 5| Osteogenesis and adipogenesis of cryopreserved plastic-adherent dermal cells isolated. 
Cryopreserved, plastic-adherent dermal cells from infant foreskin were thawed and seeded into 48-well plates 
(1x10
4
 cells/well), cultured till confluency and then incubated with appropriate induction media. After 21 days in 
culture with, the cell-layer was stained with alizarin red for detection of osteoblasts or Oil Red O to identify 
adipocytes. Pictures were captured with a light microscope, magnification x20, inset magnification x40. A| Arrows 
denote nodules with strong mineral deposition and arrowheads depict adipocytes in B| (negative controls on the 
right). 
4.22 Flow cytometry 
4.22.1 Extracellular staining protocol 
For the analysis of cell surface antigens, single cell suspensions were washed, subsequently 
resuspended with FACS buffer and 1x106 cells/100 µl were transferred into U-bottom tubes. 
Fluorochrome-conjugated mAbs were added, tubes were vortexed and incubated on ice for 
30 min in the dark. After a washing step with 1 ml of FACS buffer and centrifugation for 5 min 
at 2,500 rpm, the supernatant was discarded by gently inverting the tubes, the pellets were 
resuspended in the remaining buffer (~100 µl) and kept on ice till analysis. Isotype-matched 
control mAbs were used to determine the specifity, dead cells were excluded by examining 
the uptake of 7-amino-actinomycin D (7-AAD). 
4.22.2 Intracellular staining protocol 
Bring all buffers and PFA to RT before usage. 
1.) Wash cells with 1 ml of 1x PBS, centrifuge (5 min, 2,500 rpm) and resuspend the pellet 
with FACS washing buffer I. 
2.) Transfer 1x106 cells/100 µl to a FACS tube. 
3.) For double staining with mAbs that are directed against extracellular molecules, add now 
the mAb (or the isotype control), vortex and incubate on ice in darkness. 
4.) Wash once again with 1 ml FACS washing buffer I and pipet off the supernatant 
completely. 
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5.) Resuspend with 100 µl of 4% PFA and incubate at RT for 15 min (darkness). 
6.) Wash twice with 1 ml FACS washing buffer I. 
7.) Resuspend the pellet in 100 µl FACS permeabilisation buffer and incubate for 15 min in 
the dark at RT. 
8.) Wash once with 1 ml FACS washing buffer II and resuspend the pellet with 50-100 µl of 
the same buffer. 
9.) Add the specific mAb or the isotype control, vortex and incubate for 20 min at RT, 
protected from light. 
10.) Wash the cells 2 times with 1 ml FACS washing buffer II 
11.) Resuspend the pellet in FACS buffer and keep cells on ice till flow cytometric analysis. 
Flow cytometry was performed using a LSR II (running FACS Diva) and analyzed with 
FlowJo V 8.8.6 for Macintosh or FlowJo V 7.2.5 for Windows. 
4.23 Proliferation assay with CFSE 
CFSE is a fluorophore derivative of fluorescein that is able to diffuse passively into cells and 
bind covalently to free amines inside the cytoplasma(176). Unattached molecules exit the cell 
by the same mechanism as they enter and can be washed away. Once bound, CFSE is 
accessible for endogenous esterases that cleave its acetate groups, producing a molecule 
that is capable of emitting light in the visible spectrum (Fig. 6| A|). The molecule is excitated 
at 492 nm and emits green light with a wavelength of 517 nm. Hence, it allows the 
simultaneous staining of cells with Abs conjugated to other fluorophores, as PE (emits 
yellow/orange light, at 578 nm) or APC (emits dark red light around 661 nm; compare with 
the spectrum in Fig. 6| B|). 
 
 
 
 
 
 
 
Fig. 6| Molecular structure of CFSE and its spectral working area. A| CFSE in its inactive, colorless form. 
After cleavage of the acetate groups, the molecule is able to perform its fluorescent activities. (Adopted from 
Molecular Probes, Invitrogen
(177)
). B| Visible Spectrum. Surrounded nanometer area equates to the spectral band 
occupied by CFSE. (Adopted from Emory University
(178)
). 
There is a great variety of applications(179, 180) for fluorescent cell division markers, such as 
CFSE. Well established are isotype switch analyses of B cells following stimulation under 
A B 
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certain conditions(181, 182). But also other lymphocytes, like T cells, are subject to investigation 
with CFSE as they constitute a clearly defined population in peripheral blood that highly 
improves peak resolution as has been reported previously(183). As a result of the 
cytoplasmatic segregation during cell division, the intracellularily bound CFSE is partitioned 
equally among daughter cells, therefore they emit with halved fluorescence intensity 
(Fig. 7|). 
 
This method allows us to monitor and measure the mitotic activity by successive twofold 
reduction in fluorescence intensity and the definition of dividing cells proportional to 
undivided ones(184). Further, the relationship between proliferation and differentiation can be 
assessed in one single experiment(182), as it is additionally possible to investigate the 
expression of other extracellular markers or cytokine expression by flow cytometry(185). 
4.23.1 CFSE staining protocol 
1.) Wash PBMCs with 1x PBS. 
2.) Centrifuge at 1400 rpm for 5 min. 
3.) Meanwhile thaw an aliquot of the 5 mM CFSE-stock solution in your hand (to fasten the 
process). 
4.) Add 10 µl of the CFSE-solution to 990 µl PBS, the stock should be refrozen immediately. 
5.) Resuspend the pellet in 990 µl of PBS and add 10 µl of the 1:100 CFSE-dilution and mix 
well. 
6.) Incubate the cells for 10 min at 37°C, protected from light. 
7.) Wash at least once with ice-cold NCM (use at least 10 times of the staining volume). 
8.) Resuspend the pellet in NCM and immediately use cells for proliferation assays or keep 
refrigerated. 
4.23.2 Coating of plates with CD3 mAbs 
For coating of round-bottom 96-well plates, frozen aliquots of a mouse anti-human CD3 mAb 
were thawed, diluted with 1x PBS to obtain a concentration of 1 µg/ml, unless otherwise 
noted. Fifty µl of this Ab dilution were pipetted in each well, incubated for 2 hours at 37°C 
(humified incubator) or o/n at 4°C, washed at least 4 times with 150-200 µl of prewarmed 
Fig. 7| Typical cell division profile for CFSE-
stained PBMCs. Human PBMCs were incubated with 
CFSE (0.5µM) and then stimulated with mAbs against 
CD3 (1 μg/ml, plate-bound) and CD28 (1 μg/ml, 
soluble) at a cell density of 5x10
4
 cells/well in a 96-
well round-bottom plate. After 5 days of culture, cells 
were harvested and analyzed by flow cytometry. In 
A| data are expressed as a histogram, in B| as dot 
plot with counterstaining and 10,000 living cells were 
recorded. 
CFSE 
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1x PBS and used immediately or stored for up to 2 hours in the fridge, covered with 1x PBS 
to avoid drying-out. 
4.23.3 Experimental set up 
Frozen aliquots of bone marrow and dermal cells (all passage 1) were thawed quickly in a 
37°C waterbath, washed with medium and seeded in 225 cm3 culture flasks, at 
approximately 1x106 cells per flask in 20-30 ml of corresponding medium. After culturing o/n 
at 37°C with 5% CO2, cells were trypsinized like described before, washed with the 
appropriate medium and centrifuged (7 min, 1400 rpm). The pellet was resuspended in 1-
5 ml medium (depending on the size) and put on ice immediately. Cells were irradiated 
[1x30 Gray (Gy)] and viable cells were pipetted in each well of an CD3-coated round-
bottom 96-well microtiter plate in a total volume of 100 µl, unless stated otherwise. Cells 
were allowed to adhere o/n at 37°C, humified. On the next day, freshly isolated PBMCs were 
depleted of CD25+ cells, and/or enriched for CD3+CD4+CD45RA+ or used as whole fraction, 
stained with CFSE and 5x104 cells (in a volume of 100 µl NCM) were seeded into each well 
of the microtiter plates, with or without a soluble CD28 mAb (1 µg/ml). 
For analysis of soluble factors that might be involved in immunomodulation, the supernatant 
was transferred into CD3-coated wells after the o/n culture, the remaining cells were 
covered with fresh medium, other fractions were left with the supernatant for direct 
comparison. 
To exclude false inhibitory results, created by sterical hindrance, HEK 293 and/or HaCaT 
cells were used as control cells and were handled the same way. Further, CD3/CD28-
coated Dynabeads (Fig. 8|) were used for stimulation of T cells in coculture with bone 
marrow and dermal cells to exclude a “nonspecific” blocking of the CD3 mAb by adherent 
cells. In brief, beads were resuspended in the original vial carefully before usage, the 
appropriate amount was taken and washed with an equal amount (or at least 1 ml) of 
Dynabead buffer by resupending the beads several times. The tube was placed into a 
magnet (EasySep) for 1 min and the supernatant was discarded by quickly inverting the tube 
(with the magnet). The tube was removed from the magnet and the beads were resuspended 
in the same volume of medium as the initial volume, taken from the vial. Cell proliferation 
was stimulated by adding 25 µl Dynabead suspension to 1x106 cells to obtain a bead-to-cell 
ratio of 1:1, resuspended and 5x104 cells/well were seeded in round-bottom 96-well plates 
(total volume 100 µl), incubated for 4 or 5 days, harvested and analyzed by flow cytometry. 
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Fig. 8| Principle of T cell stimulation with Dyna-
beads. Dynabeads are small super-paramagnetic 
polymer particles that mimic APCs by stimulating 
proliferation of T cells giving both, the primary signal 
(CD3  chain of the TCR) and the secondary signal 
(costimulation by binding the cell surface molecule 
CD28). (adopted from Invitrogen
(186)
) 
 
 
 
In addition, the following negative controls were included in the assays. T cells were 
cultivated without stimulation and without MSCs. Further, the influence of MSCs without 
stimulation (CD3 with or without CD28) was investigated. MSCs were cultured without 
T cells to exclude debris in flow cytometric analysis and the proliferation profile of stimulated 
and non-stimulated T cells without MSCs was examined. To estimate the autofluorescence 
of PBMCs they were also used unstained with or without stimulation. For each assay, 
irradiated bone marrow and dermal cells were stained with CFSE and analysed for 
successful inhibition of proliferation by flow cytometry. 
4.24 Proliferation assay with [3H]-thymidine (TdR) 
To investigate the proliferation kinetics of naive Th cells, T cells (5x10
4/200 l NCM) were 
seeded in CD3-coated 96-well round-bottom microtiter plates and costimulated with soluble 
CD28 mAb (1 µg/ml). Additionally, negative fractions were included into the experiment, 
which consisted of utterly unstimulated cells or provision of only one stimulatory or 
costimulatory signal. Proliferation was measured using an 18-hour pulse of 37 kBq/well [3H]-
TdR on days 2, 3 and 4. Microtiter plates with radioactive labeled cells were stored at -20°C 
until further processing. For cell harvesting, mictotiter plates with labeled cells were thawed 
and the amount of radioisotope incorporation was determined with a 1450 Microbeta liquid 
scintillation counter. 
For comparison of different lymphocyte subpopulations, whole PBMCs were enriched for 
CD25+ cells. The negative (CD25-depleted) fraction was further enriched for naive Th cells by 
negative selection. From each fraction, 5x104 cells were seeded into a 96-well plate with or 
without bone marrow cells, stimulated with CD3/CD28-coated beads and incubated for 4 
days until radioactive labeling and measurement of [3H]-TdR uptake. 
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4.25 Statistical analysis 
Data analysis was performed in GraphPad Prism5. For a minimum, triplicates were analyzed 
by the Mann Whitney test and P > 0.05 was considered as significant. For evaluation of 
standard errors (SED) or standard deviations (SD), data were imported in Prism and 
analyzed via the column statistics program. Data are expressed as mean expression in 
%±SED (or mean%±SD, when indicated). 
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Table 4| mAbs & 2
nd
 step reagents 
Ab specifity Clone Ig class 
Working 
dilution 
Source Conjugate 
Flow Cytometry 
CD3 SK7 mouse IgG1 1:50 BD Pharmingen APC, FITC 
CD4 M-T466 mouse IgG1 1:50 Miltenyi Biotec PE 
CD25 4E3 mouse IgG2b 1:20 Miltenyi Biotec APC, Biotin 
CD26 M-A261 mouse IgG1,  1:100 BD Pharmingen PE 
CD31 WM59 mouse IgG1 1:50 Serotec FITC 
CD34 AC136 mouse IgG1,  1:100 Miltenyi Biotec FITC 
CD45RA T6D11 mouse IgG2b 1:200 Miltenyi Biotec FITC 
CD73 AD2 mouse IgG1,  1:50 BD Pharmingen purified, PE 
CD80 L307.4 mouse IgG1,  1:20 BD Pharmingen FITC 
CD86 2331 (FUN-1) mouse IgG1,  1:20 BD Pharmingen FITC 
CD90 F15-42-1 mouse IgG1,  1:100 AbD Serotec purified 
CD90 5E10 mouse IgG1,  1:200 BD Pharmingen PE 
CD105 166707 mouse IgG1 1:50 R&D FITC 
CD271 C40-1457 mouse IgG1,  1:50 BD Pharmingen PE, purified 
CD271 ME20.4-1.H4 mouse IgG1 1:50 Miltenyi APC 
FoxP3 259D/C7 mouse IgG1 1:5 BD Pharmingen AF647 
HLA-A,B,C G46-2.6 mouse IgG1,  1:50 BD Pharmingen FITC 
HLA-DR L243 mouse IgG2a 1:500 BD Pharmingen APC, FITC 
Immunofluorescence & Immunohistochemistry 
-SMA 1A4 mouse IgG2a 1:50 Sigma FITC 
-III-tubulin TU-20 mouse IgG1 1:50 Chemicon  
CD10 SS2/36 mouse IgG1,  1:50 Dako FITC 
CD34 AC136 mouse IgG1,  1:100 Miltenyi Biotec FITC 
CD45RA T6D11 mouse IgG2b 1:200 Miltenyi Biotec FITC 
CD56 Leu-19 mouse IgG1 1:10 BD Pharmingen purified 
CD73 AD2 mouse IgG1,  1:50 BD Pharmingen PE 
CD90 5E10 mouse IgG1,  1:100 AbD Serotec PE 
CD105 166707 mouse IgG1 1:50 R&D FITC 
CD271 C40-1457 mouse IgG1,  1:100 BD Pharmingen APC, PE 
Col-IV MAB1430 mouse IgG1 1:250 Chemicon purified 
GFAP 6F2 mouse IgG1 1:50 Dako FITC 
Oct-4 Poly6319 rabbit IgG 1:50 Biolegend purified 
2
nd
 step reagents 
mouse F(ab’)2 fragment 1:250 Invitrogen AF488 
mouse F(ab’)2 fragment 1:500 Invitrogen AF546 
mouse F(ab’)2 fragment 1:500 Invitrogen AF647 
Nucleic acid staining 
7-AAD   1:400 Sigma PerCP 
DAPI   1:3 Sigma Vectashield UV detection 
Sytox   1:1x10
6
 Molecular Probes Orange 
T cell stimulation 
CD3 UCHT-1 mouse IgG1 1:200 Beckman Coulter purified 
CD28 L293 mouse IgG1,  1:500 BD Pharmingen purified 
ABD SEROTEC, Düsseldorf, GER; BECKMAN COULTER, Brea, CA, USA; BIOLEGEND, San Diego, CA, USA; BD 
PHARMINGEN, San Jose, CA, USA; CHEMICON, Billerica, MA, USA; DAKO, Golstrup, DK; INVITROGEN, Carlsbad, CA, 
USA; MILTENYI, Bergisch Gladbach, GER; MOLECULAR PROBES , Eugene, OR, USA; R&D, Minneapolis, MN, USA; 
SIGMA VECTASHIELD, Burlingame, CA, USA. 
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5 Results 
5.1 In situ characterization of MSC subsets in human dermis 
Because most of the studies have only characterized culture expanded MSCs, isolated from 
diverse tissues, the equivalent cells have not been identified in vivo and little is known about 
their exact tissue location. Encouraged by our in vitro findings that phenotypically-defined 
MSC subsets can be isolated from human dermis, markers known to be expressed on BM-
MSCs, such as CD73, CD90, CD105 and CD271 were used to visualize these cells in 
juvenile foreskin. CD73+ cells were mostly found in the upper dermis, close to the 
epidermal/dermal junction (Fig. 9|). CD90+ and CD105+ cells were present in the upper and 
lower part of the dermis (Fig. 9|). The mAb against CD271 stained fine nerve endings close 
to the epidermis (not shown) and huge, bulky formations in the middle and deep dermis 
(Fig. 9|). 
 
Fig. 9| Localizing cells expressing MSC markers in human foreskin. Immunofluorescence analysis of the 
indicated markers on cryostat sections from juvenile donors (aged between 2-13 years). PE emission was 
enhanced with AlexaFluor546, nuclei were stained with DAPI and specifity was confirmed with isotype-matched 
controls. Pictures were captured with a CLSM. E = epidermis, D = dermis, scale bars = 20 µm 
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For the identification of MSCs, it is crucial that a combination of certain surface molecules is 
co-expressed. As shown in Fig. 10| around halve of the cells expressing CD271 are positive 
for CD90 in the upper and deep dermis. These findings nicely correlate with flow cytometric 
data of plastic-adherent total dermal cells (C. Vaculik et al., manuscript in preparation). 
 
Fig. 10| Around 50% of the cells positive for CD271 coexpress CD90. This representative 
immunofluorescence double labeling was performed on cryosections of a 4-year-old donor and analyzed with 
CLSM. Arrows denote CD271
+
CD90
+
 double positive cells detected in close proximity to the epidermis (upper 
panel) or in deeper dermal layers (lower panel). Specifity was confirmed with isotype-matched controls. E = 
epidermis, D = dermis, scale bars = 20 µm 
To further characterize the nature of CD90+CD271+ cells, we performed triple staining 
including the MSC marker CD73. Indeed, few CD73+CD90+CD271+ cells could be located in 
the upper-mid-dermis (Fig. 11|, arrows) and the deep dermis (Fig. 12|, arrows). The 
majority of cells, however, was only double positive for CD73 and CD90 (over 90%). It is 
noticeable that all CD271+ cells expressed CD73 and that most of these cells also expressed 
CD90 in three donors investigated. 
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Fig. 11| CD73
+
CD90
+
CD271
+
 cells are present in the upper, papillary dermis of. Close to the epidermis of 
juvenile foreskin few cells were positive for all three markers, while many cells expressed CD73
 
and CD90. 
Arrows indicate CD73
+
CD90
+
CD271
+
 cells. CD73-PE was enhanced with AF546 and pictures were captured with a 
CLSM (n=3, aged between 2-10 years). E = epidermis, D = dermis, scale bar = 20 µm 
 
Fig. 12| CD73
+
CD90
+
CD271
+
 cells can be localized in the deep dermis. Triple labeling identified few 
CD73
+
CD90
+
CD271
+
 cells (arrows) and many CD73
+
CD90
+
271
-
 cells. Scale bar = 20 µm 
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5.1.1 CD271+ cells do not coexpress CD34 but are localized in close association 
with cells expressing this antigen 
Based on the elongated structures formed by CD271+ and CD90+ cells found in all 
investigated skin donors, we decided to proceed with double and triple staining including 
mAbs directed against CD34
d
 and type IV collagen
e
 (Col-IV) to further unravel the nature of 
CD271+ cells. Double labeling of CD34 and CD271 in cryosections showed ambiguous 
staining results. On the one hand, many longitudinal structures could be identified with cells 
that seemed to be double positive for CD34 and CD271 in the upper dermis (Fig. 13|, 
arrows) and single CD271+ cells in-between. On the other hand, we found many circular 
structures in the deep dermis, which were CD271+CD34- (Fig. 13|). 
 
Fig. 13| CD271
+
CD34
+
 cells as well as CD271
+
CD34
-
 cells are present in the dermis. Arrows denote 
CD271
+
CD34
+
 cells in the subepidermal papillary dermis. Pictures are representative of at least two different 
experiments. Nuclei were stained with DAPI. Scale bars = 20 µm 
Because vertical tissue staining could not clarify, whether CD271+ cells indeed coexpress 
CD34, we employed another strategy to address this question. Using CLSM, dermal sheets 
allow the imaging of cell networks with all their complexity and topological relationship to 
other tissue components within whole tissue. Fig. 14| clearly shows, that CD271 is never 
coexpressed with CD34, though often colocalized (arrows). Both build discrete exceeding 
                                                 
d
 Besides its expression in HSCs, CD34 is known to be expressed on endothelial cells of blood vessels and 
lymphatics, perivascular stroma
(187)
 and a small proportion of BM-MSC progenitors
(188)
. 
e
 This marker is expressed primarily in basement membranes, more precisely the lamina densa of its basal 
lamina, surrounding mostly blood vessels and lymphatics, but also in all epithelia and the nervous system
(189, 190)
. 
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networks throughout the dermis. This confirms the independent existence of CD271+ cells 
from vascular bundles in human skin. 
 
Fig. 14| Immunofluorescence double labeling confirmed autonomy of CD271
+
 cells by three-
dimensional illustration of the dermis. Foreskin was incubated on ammoniumthiocyanate solution and after 
one hour, the epidermis was removed from the dermis, which was fixed with PFA, permeabilized with Triton-X 
and stained with the indicated mAbs or the respective isotype control. Dermal sheets were analyzed by CLSM. 
Arrows denote sites of colocalization of CD271
+
 and CD34
+
 cells. Scale bar = 10 µm 
Interestingly, the inclusion of a mAb against Col-IV revealed that several CD271+ cells 
coexpress this marker in the subepidermal papillary, mid- and deep dermis (Figs. 15|-17|, 
arrowheads). Some cells expressing CD271 only, could be found in the deep dermis 
(Fig. 16|, arrows and Fig. 17| A|), along with cells that were assembled into big rounded 
structures in the deep dermis, which coexpressed Col-IV (Fig. 17| B|, arrowheads). In 
contrast, CD34+CD271+Col-IV+ cells were hardly detectable (Fig. 17| A|, asterisks), 
whereas CD34+ cells were almost invariably surrounded by Col-IV+ cells (Figs. 15|-17|). 
Remarkable is the finding that CD271+ cells always formed circular structures in the deep 
dermis, often colocalized with Col-IV (Fig. 17| B|). Due to their shape, these structures 
could represent cross-sections of vessels, peripheral nerve bundles, but also sebaceous and 
sweat glands, since expression of CD271 has been reported for all of these skin 
components(164). 
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Fig. 15| Close to the epidermis CD271
+
 cells express extracellular matrix receptors. Immunofluorescence 
staining of foreskin with mAbs directed against CD34, CD271 and Col-IV identified several double positive cells 
for CD271 and Col-IV (arrowheads), but rarely coexpression with CD34. E = epidermis, D = dermis, scale bar = 
20 µm 
 
Fig. 16| Human dermis harbors CD271
+
Col-IV
+
CD34
-
 cells, but also single CD271
+
 cells. Cryosections of 
juvenile foreskins (aged between 2-13 years) were stained with mAbs directed against Col-IV, CD34 and CD271. 
Arrows denote CD271
+
 cells, arrowheads CD271
+
Col-IV
+
 cells. Scale bar = 20 µm 
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Fig. 17| CD271
+
Col-IV
+
CD34
-
 cells colocalize with CD34
+
 cells in the deep dermis. Triple labeling of 
cryosections revealed cells double positive for CD271 and Col-IV (arrowheads in A| B|), colocalized with CD34
+
 
cells. A| Triple positive cells are denoted with an asterisk, while arrows in A| B| point out CD271
+
 single positive 
cells. Scale bars = 20 µm 
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5.1.2 The morphology of dermal single cells in culture is mostly, but not entirely 
MSC alike 
Due to our observations that plastic-adherent dermal cells share a lot of features and 
markers with MSCs from bone marrow, we selected key markers known to be expressed on 
BM-MSCs to further characterize the morphology of isolated dermal cells by 
immunofluorescence. To address this, adherent dermal cells (passage 2) were placed in 
chamber slides and incubated for 2-3 days, fixed, stained and then analyzed. Expanded cells 
stained with Mai-Grünwald/Giemsa illustrated a typical fibroblastoid appearance (Fig. 18|, 
upper panel, left) similar to that described for BM-MSCs and mesenchymal progenitor cells 
from other tissues(191). Elongated spindle-shaped or rhomboid cells with a central nucleus 
were predominant. Almost all cells expressed CD73, CD90 and CD105 (Fig. 18|), confirming 
published data. Morphologically, the rhomboid shape with adherent pseudopods was most 
abundant. Arrowheads denote cell to cell junctions between CD105+ cells. Few cells also 
expressed the mesenchymal marker -SMA, which is an actin microfilament of smooth 
musculature, like heart. The transcription factor Oct-4, which is normally specific for 
undifferentiated ESCs, was also present in the nuclei of a few adherent dermal cells 
(Fig. 18|). Interestingly, CD271+ cells appeared in two different morphologic shapes in vitro 
(Fig. 18|, lowest panel). Most of the cells revealed a MSC-like morphology (Fig. 18|, lowest 
panel, left picture). Some cells, however, had small cellular bodies with long, branched 
extensions, comparable with neuronal dendrites (Fig. 18|, middle and right picture). In 
summary, the visualization of single cells in culture revealed basically the expected 
morphology of MSCs, beside some sporadic CD271+ cells resembling the morphology of 
neuronal cells. 
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Fig. 18| Morphologic characterization of MSC subsets. Juvenile dermal cells from foreskin (passage 2) were 
seeded (3x10
4
 cells/cm
2)
 in chamber slides and expanded for 2-3 days. Cells were fixed with MetOH and 
subsequently stained with Mai-Grünwald/Giemsa (LM, magnification x20) or the indicated mAbs. For 
immunofluorescence analysis, nuclei were stained with DAPI and all signals were enhanced with Alexa Fluor 
(AF488 for FITC or AF546 for PE) and analyzed with a CLSM. Scale bars = 20 µm 
5.1.4 The dermis harbors CD271+CD56+ and CD271+-III-tubulin+ cells and cells 
single positive for CD271 in close association with cells expressing 
neuronal/glial markers 
To further unravel the characteristics of CD271+ cells, we included NCAM (CD56) in our 
analysis and is known to be expressed on NK cells, neurons and glial cells. First, single 
staining on cryosections was performed to analyze the distribution of anti-CD56-reacting 
cells in foreskin. We found that the mAb marks certain cells and structures throughout the 
dermis (Fig. 19|). Close to the epidermal-dermal junction, many fine structures were found, 
possibly representing nerve endings (Fig. 19| A|). In the mid- and deep dermis 
(Fig. 19| B|) big, bulky structures that looked like multiple cell layers, could be found, 
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possibly representing cross-sections of peripheral nerves or mechanoreceptors of glabrous 
skin, such as Meissner’s or Pacinian corpuscles, Merkel’s discs(145) or Ruffini corpuscles. 
 
Fig. 19| Dermal cells of the upper and deep dermis express CD56. Cryosections from foreskin were 
incubated with a primary mAb against CD56 and visualized with goat-anti-mouse AF488. Shown is one 
representative experiment of at least 4 independent experiments. Nuclei were stained with CytoxOrange and 
pictures were captured with a CLSM (A| upper dermis, B| lower dermis). Scale bars = 20 µm 
Double staining confirmed our hypothesis about CD271+ nerve endings in the papillary 
dermis, as we indeed identified CD271+CD56+ cells (Fig. 20| A|). In the deep dermis, 
CD271+ cells mostly colocalized with cells expressing this glial/neuronal marker. CD56+ 
structures/cells were always found to be surrounded by CD271+ cells in the deep dermis 
(Fig. 20| B|). Very rarely, single cells positive for CD271 or CD271+CD56+ cells (Fig. 20| 
B|, asterisks) could be detected in dermal tissue. 
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Fig. 20| CD271
+
 cells colocalize with CD56
+
 cells in human dermis. A| CD56
+
 and CD271
+
 cells colocalized 
in the upper dermis, B| as well as in the deep dermis (asterisks). Nuclei were stained with CytoxOrange and 
pictures were analyzed by CLSM. All pictures are representative of at least four different experiments with juvenile 
foreskin (aged between 2-13 years). E = epidermis, D = dermis, scale bars = 20 µm 
Because CD56 is a neuronal and glial marker, further mAbs were introduced to discriminate 
neurons and glial cells. -III-tubulin is a neuron-associated protein expressed in cells of the 
central as well as in the peripheral nervous system, but was believed not be expressed in 
healthy human skin(192). Recent studies(193) and our findings, however, revealed that the mAb 
against -III-tubulin stained similar cell aggregates in the deep dermis like the anti-CD56 
mAb (Fig. 21|). 
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Double staining with an anti-CD271 mAb showed the same occurrence in epidermal vicinity, 
as has been shown for CD56 (Fig. 22|). Cells positive for -III-tubulin formed delicate, 
“capillary-like” structures in the upper dermis, surrounded by CD271+ cells, some single cells 
coexpressed CD271 (Fig. 22| A|, arrowheads). Again, rounded, bulky cell aggregates, also 
encapsulated by cells expressing CD271 (B|), including some CD271+-III-tubulin+ cells 
(Fig. 22| B|, arrowheads), could be found in the deep dermis, whereas few cells were single 
positive for CD271 with no colocalisation (Fig. 22| A| B|, arrows). 
 
Fig. 22| Double staining of CD271 and -III-tubulin. The apparent colocalisation of -III-tubulin- and CD271-
expressing cells in A| the upper and B| the deep dermis is almost equal to the staining pattern of CD56-
expressing cells. Arrows denote CD271
+
 cells, whereas arrowheads depict CD271
+
-III-tubulin
+
 cells. E = 
epidermis, D = dermis, scale bar = 20 µm 
Fig. 21| The distribution of -III-tubulin
+
 dermal cells is 
similar to the staining pattern of CD56
+
 cells. Cyrosections 
were stained with a FITC-conjugated mAb directed against the 
neuronal marker -III-tubulin, nuclei were counterstained with 
CytoxOrange and pictures captured with a CLSM. Scale bar = 
20 µm 
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The protein GFAP is a member of the type III intermediate filaments and primarily expressed 
by cells of the central and peripheral nervous system, like Schwann cells and, in a small 
percentage, on BM-MSCs(194). GFAP+ cells could be detected in the deep dermis, but with 
very low intensity. CD271+ cells colocalized with GFAP+ cell structures and infrequently 
CD271+GFAP+ cells could be detected that looked like cross-sectioned nerves (Fig. 23|), but 
the majority of CD271+ cells do not express GFAP and vice versa. 
 
Fig. 23| Few CD271
+
GFAP
+
 cells are present in human dermis. Immunofluorescence double labeling of 
GFAP and CD271 showed a colocalization of cells expressing these markers throughout the dermis. Occasionally 
CD271
+
GFAP
+
 cells were found (arrows). Scale bar = 20 µm 
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5.2 Immunomodulatory potential of dermal MSC subsets 
5.2.1 Phenotypic comparison of plastic-adherent bone marrow and dermal cells 
from different donors 
According to the minimal criteria(85) to characterize multipotent MSCs, they are defined as 
plastic-adherent cells that express CD73, CD90 and CD105, but lack the expression of HLA-
DR and several other surface proteins and can differentiate into adipocytes, chondrocytes 
and osteoblasts in vitro. In our lab, Dr. Christine Vaculik established methods for the 
prospective isolation and characterization of stem/progenitor cells in human dermis. She 
confirmed the existence of dermal cells, which fulfill these criteria (C. Vaculik, manuscript in 
preparation). Fig. 24| shows the flow cytometric comparison of BM-MSCs (A|) and primary 
dermal cells (B|), which were both preselected for plastic-adherence. The three major CD 
markers described for BM-MSCs are also present on adherent dermal cells in comparable 
percentages (Fig. 24|, black histograms). Over 90% of plastic-adherent dermal cells are 
strong positive for CD90, nearly 100% are positive for CD73 and CD105, but lack the 
expression for HLA-DR. This profile makes these cells perfect candidates for further 
immunomodulatory investigations. 
 
Fig. 24| Detection of MSC markers on plastic-adherent human dermal cells. Flow cytometry of plastic-
adherent A| bone marrow cells and B| dermal cells (6 years, unpassaged) was performed by incubating single 
cell suspensions with the appropriate mAbs (black histograms) and isotype-matched controls (grey histograms). 
Dead cells were excluded with 7-AAD. Histograms are representative of at least 7 different experiments. 
To further characterize the marker expression pattern of dermal cells, well-known markers 
described to be present and absent (CD80, CD86) on BM-MSCs were used. To delineate 
dermal MSCs, further markers were included such asCD31 and CD34. As CD271 is 
expressed on a small proportion of MSCs as well(195), we included this marker in our further 
experiments. Table 5| shows plastic-adherent dermal cells from seven individuals, uniformly 
expressing CD73, CD105 and HLA-A,B,C. This was comparable with the expression profile 
of bone marrow cells. Skin donors, however, were heterogeneous for CD26, CD90 and 
CD271, as demonstrated by high SED values. On both, dermal and bone marrow cells, 
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HLA-DR was minimally expressed and the CD28 ligands CD80 and CD86 were completely 
absent (Fig. 25|). Compared with bone marrow cells, the mean expression of CD271 in 
dermal cells was much higher, whereas CD90 was not uniformly expressed in dermal cells 
(about 10-15% lower than in bone marrow cells). These data demonstrate the similarity of 
adherent dermal cells to bone marrow cells, but also highlight some differences, especially 
for the marker CD90, which is one of the most prominent molecules to describe MSCs, and 
for CD271. The inhomogeneous marker expression in different donors makes it difficult to 
compare single individuals with each other, underlining the need of multiple donor 
comparisons. 
Table 5| Marker expression of dermal and bone marrow cells 
 plastic-adherent 
Markers DERMAL CELLS 
BONE MARROW 
CELLS 
CD26 32.29±6.48 30.52±9.10 
CD31 0.22 1.40 
CD34 5.22 1.54±0.28 
CD73 99.59±0.12 99.85±0.04 
CD80 0.27±0.08 0.10±0.04 
CD86 0.69±0.18 0.41±0.09 
CD90 89.59±4.99 99.48±0.24 
CD105 97.94±0.74 99.44±0.25 
CD271 22.34±6.88 8.10±2.39 
HLA-A,B,C 99.74±0.07 99.76±0.06 
HLA-DR 1.70±0.32 1.21± 0.48 
Whole dermal cells isolated from foreskin (n=7, aged between 2 and 9 years) and bone marrow cells (n=1) were 
expanded until 80-90% confluency, frozen and stored in liquid nitrogen until further processing. For analysis by 
flow cytometry, cells were thawed, cultured for 1-3 days and analyzed for marker expression as indicated. Single 
staining were made by incubation of 1x10
6
 cells with the indicated mAbs and at least 10,000 cells were recorded 
for every single sample. Isotype-matched controls were used to confirm specifity. Data are expressed as 
mean%±SED. 
5.2.2 Phenotypic characterization of distinct MSC subsets in human dermis upon 
cryopreservation 
Based on our previous observations, we analyzed distinct dermal subpopulations for their 
immunomodulatory potential. CD73+ and CD90+ dermal cells were selected due to their 
known capability to mediate leukocyte and lymphocyte adhesion to endothelium(97, 196-199), as 
we found that our cells of interest were prevalently located close to vascular cells. Further, it 
has been shown for BM-MSCs that the immunosuppressive capacity is lost with decreasing 
positivity for CD90(200). Our finding that most of the CD271+ dermal cells were also positive 
for CD73 and/or CD90 and that many CD271+ cells colocalized with cells positive for Col-IV, 
a marker expressed in the basement membrane of lymphatic vessels, persuaded us to 
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include this cell subset into our experiments. Additionally, CD271 is a suitable marker to 
isolate MSCs from primary tissues as has been described previously(201). In the first set of 
experiments, freshly isolated dermal cells were enriched for CD73-, CD90- and CD271-
expressing cells with MACS columns (Figs. 26|-28| A|). Subsequently, positive and 
negative fractionsf, as well as total dermal cells were expanded in culture and cryopreserved 
until further investigations. For flow cytometric analysis and functional assays, cells were 
thawed and left to adhere o/n to tissue culture plates, trypsinized the next day and tested for 
marker expression, as shown in Figs. 26|-28| B|. Single staining were performed to detect 
and quantify CD80, CD86, HLA-A,B,C and HLA-DR, CD26, CD73, CD90, CD105 and CD271 
expression in enriched and depleted cell suspensions compared with total dermal cells and, 
in certain experiments, bone marrow cells. Common in all experiments was the observation 
that total dermal cells did not express the costimulatory molecules CD80 and CD86 
(Fig. 25|). 
  
The expression profile of plastic-adherent CD73+ cells after thawing and expansion did not 
vary greatly from CD73- cells and total dermal cells concerning the markers CD105, CD90, 
HLA-A,B,C and HLA-DR (Fig. 26| B| and data not shown). Surprisingly, the expression of 
the marker CD73 in positive and negative fractions was almost equal in all experiments 
performed, although they were initially highly purified, as can be seen by flow cytometric data 
acquired directly after the enrichment process, implying that CD73+ cells proliferated better 
than CD73- cells before freezing (Fig. 26| A|). This hypothesis was confirmed by the 
observation that nearly 100% of plastic-adherent total dermal cells expressed CD73. 
Differences, however, were observed regarding the expression of CD26 and CD271. The 
percentage of CD26+ dermal cells dropped after the enrichment procedure for CD73+ and 
CD73- cells. Repeatedly, CD73- cells expressed marginally higher levels of CD26 than cells 
positive for CD73. This finding was more pronounced in experiments using other markers for 
enrichment (Fig. 27| and Fig. 28|). Further, we found that CD73+ and CD73- cell fractions 
almost equally expressed CD271. 
                                                 
f
 To simplify matters, enriched fractions were called „positive“, whereas depleted fractions were termed „negative“, 
although both fractions could not be totally enriched or depleted for cells expressing the “one and only” marker 
with the methods used. 
Fig. 25| Adherent dermal cells did not express 
the costimulatory molecules CD80 and CD86. Total 
dermal cells were isolated and cultured. Adherent 
cells were expanded and snap-frozen in liquid 
nitrogen. For flow cytometric analysis, cells were 
thawed, left to adhere o/n, detached via trypsinisation 
and subsequently analysed. Black profiles illustrate 
the reactivity of relevant mAbs, whereas grey profiles 
represent isotype-matched controls. Dead cells were 
excluded with 7-AAD and 10,000 living cells were 
recorded. 
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Fig. 26| Enrichment profile and marker analysis of whole dermal cells, enriched cells expressing CD73 
and CD73-depleted cell populations upon cryopreservation. A| Freshly isolated primary dermal cells (6 year-
old foreskin) were labeled with an CD73 mAb, enriched with MACS columns and one part of cells was analyzed 
by flow cytometry as shown, the other part was expanded in culture. After expansion, cell fractions were stored in 
liquid nitrogen until further investigations. Upon thawing cells were expanded again and single staining with the 
indicated mAbs were made and examined by flow cytometry. B| Colored, open profiles represent the specific Ab 
expression. CD80/86 and HLA-DR expression is not shown, as no expression could be detected in all fractions. 
Specifity was controlled for every fluorochrome using isotype-matched controls (black, filled histograms). For 
overlays, y-axis were fixed to normalize the data. One representative of at least 3 different individual experiments, 
made with different skin donors, is shown. Dead cells were excluded with 7-AAD and 10,000 living cells were 
recorded for every fraction. 
The comparison of CD90+ and CD90- cells revealed no great marker variation with regard to 
CD73 (Fig. 27| B|). Surprisingly, CD90- cells showed a broader distribution of fluorescence 
emission, notably for CD105, but also for HLA-A,B,C, compared with the CD90+ cell fraction. 
The depletion of CD90+ cells, which coexpress high levels of CD105 and HLA-A,B,C, led to a 
left-over of heterogeneous cells in the CD90- cell fraction, with extremely diverse receptor 
density levels of these markers. In contrast to the enrichment with the CD73 mAb, the 
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CD90+ and CD90- cell fractions, showed remarkable differences concerning the expression 
of CD90 (Fig. 27| A| B|). Notable is further the almost entire depletion of CD26+ cells within 
the CD90+ cell fraction compared with CD90- or total dermal cells. CD271+ cells were a priori 
almost completely absent in total dermal cells, which demonstrates again the individual 
differences between human donors concerning this marker. 
 
Fig. 27| Enrichment profile and marker analysis of whole dermal cells, enriched cells expressing CD90 
and CD90-depleted cell populations upon cryopreservation. A| Freshly isolated primary dermal cells (6 year-
old foreskin) were labeled with an CD90 mAb, enriched with MACS columns and one part of cells was analyzed 
by flow cytometry as shown, the other part was expanded in culture. After expansion, cell fractions were stored in 
liquid nitrogen until further investigations. Upon thawing cells were expanded again and single staining with the 
indicated mAbs were made and examined by flow cytometry. B| Colored, open profiles represent the specific Ab 
expression. CD80/86 and HLA-DR expression is not shown, as no expression could be detected in all fractions. 
Specifity was controlled for every fluorochrome using isotype-matched controls (black, filled histograms). For 
overlays, y-axis were fixed to normalize the data. One representative of at least 3 different individual experiments, 
made with different skin donors, is shown. Dead cells were excluded with 7-AAD and 10,000 living cells were 
recorded for every fraction. 
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The phenotypic analysis of highly enriched, plastic-adherent, frozen-thawed CD271+ or 
CD271- cells showed again no major differences between the expression of CD105, CD73 
and HLA-A,B,C (Fig. 28| B|). The initial enrichment for CD271+ cells lead to a definite 
increase of CD271+ cells in the positive fraction, compared with the incomplete loss in the 
CD271- cell fraction (Fig. 28| A|). CD271+ cells contained a marginally higher percentage of 
CD26+ cells than total dermal cells, but almost halved levels compared with the depleted 
fraction. CD90 showed already in total dermis a remarkable bimodal distribution of CD90+ 
and CD90- cells, which was enhanced with the enrichment of CD271+ cells. In summary, 
approximately 50% of CD271+ cells were CD90+, while all cells negative for CD271 were 
positive for CD90. 
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Fig. 28| Enrichment profile and marker analysis of whole dermal cells, enriched cells expressing CD271 
and CD271-depleted cell populations upon cryopreservation. A| Freshly isolated primary dermal cells (6 
year-old foreskin) were labeled with an CD271 mAb, enriched with MACS columns and one part of cells was 
analyzed by flow cytometry as shown, the other part was expanded in culture. After expansion, cell fractions were 
stored in liquid nitrogen until further investigations. Upon thawing cells were expanded again and single staining 
with the indicated mAbs were made and examined by flow cytometry. B| Colored, open profiles represent the 
specific Ab expression. CD80/86 and HLA-DR expression is not shown, as no expression could be detected in all 
fractions. Specifity was controlled for every fluorochrome using isotype-matched controls (black, filled 
histograms). For overlays, y-axis were fixed to normalize the data. One representative of at least 3 different 
individual experiments, made with different skin donors, is shown. Dead cells were excluded with 7-AAD and 
10,000 living cells were recorded for every fraction. 
Altogether, the enrichment for CD90+ and CD271+ cells showed distinct expression patterns 
and were, thus, employed for a comparison of positive and depleted fractions in a coculture-
based proliferation assay of lymphocytes. Regardless of a major lack of investigated 
differences, CD73+ and CD73- cells were also included into further experiments. 
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5.2.3 Differences in the proliferation kinetics of PBMCs and naive Th cells 
The proliferative response is an essential feature of the adaptive immune response and it 
has been reported that MSCs from bone marrow and other tissues have the ability to 
modulate lymphocyte proliferation after stimulation with mitogens, allogens or direct 
engagement of the TCR complex and costimulatory molecules via Abs, such as CD3 and 
CD28, respectively. For our investigations, immobilized CD3 and soluble CD28 mAbs 
were used, as this type of stimulation is more physiological than mitogenic lectins(202). 
Most studies investigating the immunomodulatory potential of MSCs used undefined PBMC-
mixtures or pan T cells(203, 204). To test, whether there are differences in the proliferative 
response of PBMCs and naive Th cells, they were stimulated with CD3 and/or CD28 
mAbs, labeled with [3H]-TdR and harvested on days 3-6. PBMCs stimulated with CD3/CD28 
mAbs started to proliferate around day 3 (as inspected in wells), increased their proliferation 
till day 5 and decreased until day 6 (Fig. 29| A|). In contrast, naive Th cells were initiated 
through CD3/CD28 ligation to highly proliferate already before day 3 and appeared to have 
a steady proliferative response over almost 4 days, until proliferation decreased slowly 
around day 6 (Fig. 29| B|). Both lymphocyte fractions showed no response to CD28 alone 
and did not proliferate without provision of external stimuli (Fig. 29| A| B|). 
 
Fig. 29| Proliferation kinetics of PBMCs and CD4
+
CD45RA
+
 T cells with different stimuli. PBMCs and 
naive Th cells (5x10
4
/well in 200 µl NCM) were stimulated with plate-bound CD3 (2 µg/ml) alone or in 
combination with soluble CD28 (1 µg/ml) for 3-6 days in round-bottom 96-well plates. Cells were labeled with 
[
3
H]-TdR for the last 18 hours of culture and harvested. A| PBMCs had a peak proliferative response at day 5, 
while B| CD4
+
CD45RA
+
 T cells proliferated almost equally until day 6, when stimulated with CD3/CD28. d = day 
The almost constant proliferation level over a long time period renders naive Th cells highly 
suitable for investigations with CFSE, as this method allows the detection of time- or cell 
division-dependent influences by dermal MSC subtypes. In addition, a highly pre-sorted cell 
population is very advantageous for a CFSE-based cell division tracking system, as it 
improves peak resolution(183). Furthermore, to our knowledge, few reports exist for human 
BM-MSCs and none with dermal MSCs studying their impact on naive Th cells. Worth 
mentioning, is the delayed, but still strong stimulation of both responders with high 
concentrations of CD3 alone. Therefore, we decided to use lower CD3 concentrations for 
further experiments. 
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5.2.4 Establishment of a CFSE-based MSC – T cell coculture system 
5.2.4.1 Adherent dermal cells inhibit the proliferation of CD3/CD28-stimulated naive Th cells 
To elucidate the impact of dermal MSCs on naive Th cells, a coculture system for a CFSE-
based approach had to be developed. For this purpose, we used BM-MSCs as a positive 
control, as they are known to inhibit T cell proliferation. For the stimulation of naive Th cells, 
CD3-coated, round-bottom 96-well plates with/without a soluble CD28 mAb were used. 
Different concentrations of BM-MSCs (5x103-1x105 cells/well) and dermal cells (5x103, 1x105 
cells/well) were seeded and left to adhere o/n. On the next day, enriched naive Th cells 
(Fig. 30|), were stained with CFSE, added to the wells (5x104cells/well) and cultured for 5 
days with/without BM-MSCs and dermal cells. Additionally, BM-MSCs and dermal cells were 
cocultured with naive Th cells without stimulation to exclude allogeneic immune responses. 
Further, T cells and BM-MSCs were seeded alone with or without the indicated stimuli. 
Unstained T cells were used to estimate autofluorescence (data not shown). 
 
Fig. 30| Enrichment of naive Th cells from total PBMCs. Lymphocytes and monocytes were separated from 
erythrocytes and neutrophils by density gradient centrifugation of buffy coats. The resulting PBMCs (FSC/SSC 
profile, left dot plot) were stained with a mAb mixture to retain unwanted cells in the magnetic columns (negative 
fraction, middle dot plot), while untouched naive Th cells could pass (positive fraction, right dot plot). Enrichments 
were analyzed by flow cytometry by direct gating of PBMCs in the FSC/SSC profile and staining of CD4 and 
CD45RA. Purity was always between 93% and 99%. 
No allogeneic stimulation could be detected, upon coculture of BM-MSCs with Th cells 
without stimulation (Fig. 31| A|, upper panel, w/o stim) or dermal cells (see 5.2.5 and 
5.2.11). With increasing cell densities, BM-MSCs, as well as dermal cells, showed a 
remarkable inhibition of T cell proliferation, when stimulated with CD3/CD28 mAbs 
(Fig. 31| A| B|). Interestingly, a small T cell population was proliferating even without 
costimulation, which was enhanced by low concentrations of BM-MSCs and dermal cells 
(Fig. 31|, CD3). This phenomenon could be seen with little variations in every experiment 
performed and could reflect costimulation with remaining APCs, as the percentage of 
proliferating cells decreased with increased T cell purity. 
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5.2.4.2 High numbers of BM-MSCs inhibit the proliferation of CD3/CD28-stimulated CD25-depleted 
naive Th cells 
It has been reported that nTregs show increased proliferation upon coculture with BM-
MSCs(128, 130, 205, 206). As we were interested, whether the proliferation of defined naive Th cells 
could be altered by the addition of MSCs, we eliminated nTregs by depletion of CD25+ cells 
from total PBMCs, before the enrichment of naive Th cells. Th cell proliferation increased 
strongly upon coculture with low numbers of BM-MSCs when stimulated with CD3/CD28 
and CD3 alone (Fig. 32|, red histograms). With increasing BM-MSC densities the 
proliferation was clearly inhibited, as illustrated by a shift of the red histogram, which 
represents T cells from coculture, towards the unstimulated T cell fraction (single peak with 
highest fluorescence intensity). Interestingly, the proliferation of CD3-stimulated Th cells 
Fig. 31| CFSE dilution analysis of naive Th cells 
cocultured with BM-MSCs and dermal cells showed a 
concentration-dependent inhibition of Th cell 
proliferation. Plastic-adherent A| BM-MSCs and B| dermal 
cells were seeded at the indicated cell densities/well into 
round-bottom 96-well plates and cocultured for 5 days with 
CD4
+
CD45RA
+
 T cells (5x10
4
cells/well), without stimulation, 
stimulated with plate-bound CD3 (1 µg/ml) and with/without 
soluble CD28 (1 g/ml). CFSE dilution was measured by flow 
cytometry and compared with Th cell proliferation without 
(w/o) MSCs. The autofluorescence of Th cells was 
determined, to be able to set the gates (data not shown). 
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alone, was almost abolished (Fig. 32|), depending on the purity of CD25 depletion, which 
was verified in all experiments performed with different PBMC donors. 
 
Fig. 32| Proliferation of CD4
+
CD45RA
+
CD25
-
 T cells cocultured with BM-MSCs. Different concentrations of 
BM-MSCs were seeded into CD3 (1µg/ml) precoated plates, left to adhere o/n and cocultured with CD25-
depleted naive Th cells (5x10
4
 cells/well) with or without an CD28 mAbs (red histogram). After 5 days, cells were 
harvested, washed with FACS buffer and the CFSE dilution profile was assessed by flow cytometry. As negative 
control, unstimulated T cells were cocultured with MSCs (white peak). Stimulated T cells alone (dark grey 
histogram) served as positive proliferation control. Low numbers of BM-MSCs (1x10
3
cells/well) seemed to have 
an enhancing effect on proliferation, while high numbers around 1x10
5
/well completely abrogated the proliferation. 
The dark grey histogram in the overlays resembles Th cells after 5 days culture and 
stimulation with the indicated Abs, whereas the light grey histogram results from 
autofluorescence of unstained Th cells. 
5.2.4.3 HaCaT cells inhibit the proliferation of CD3/CD28-stimulated CD25-depleted naive Th cells 
The complete inhibition of T cell proliferation with MSC numbers around 1x105 cells/well or 
higher, lead us to critically assess the setup of this coculture system, as to our knowledge, all 
investigations of the inhibiting nature of MSCs reported by other groups showed a reduction 
of proliferation up to 90%, but never full inhibition(70, 207, 208). One possible explanation could 
be a blocking of plate-bound CD3 Abs by high densities of adherent MSCs. To test this 
hypothesis, we included HaCaT cells in our experiments, a nontumorigenic keratinocyte cell 
line that was reported to have no effect on T cell proliferation(148). BM-MSCs and HaCaT cells 
(1x104 and 1x105 cells/well) were seeded into CD3-coated 96-well plates and cultured o/n. 
At high BM-MSC densities (Fig. 33| A|, red histogram) we found nearly complete inhibition 
of T cell proliferation compared with the proliferation profile of CD3/CD28-stimulated T cells 
alone (filled, dark grey histograms). Unexpectedly, also HaCaT cells massively inhibited T 
cell proliferation (Fig. 33| B|) implying that the inhibitory effect of the cells investigated is 
due to sterical hindrance by adherent cells. Thus, CD3/CD28-coated beads were 
introduced for T cell stimulation to avoid this problem(8). 
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Fig. 33| Analysis of possible sterical hindrance caused by adherent cells using HaCaT cells. High 
concentrations of A| BM-MSCs and B| HaCaT cells (1x10
4
 and 1x10
5
 cells/well) were seeded into CD3 
precoated plates (1µg/ml) and cocultured with CD4
+
CD45RA
+
CD25
-
 cells (5x10
4
 cells/well) and a soluble CD28 
mAb, to test whether sterical hindrance by adherent cells is the inhibiting cause. 
5.2.4.4 Establishment of the CD3/CD28 bead-based stimulation 
As adherent cells seemed to block plastic-bound Abs at high densities, we employed 
CD3/CD28-coated beads in our experiments. First, the bead-cell ratio and the T cell 
concentration per well had to be determined. For this, the magnetic bead solution was 
resuspended, an aliquot was taken and washed according to the manufacturer’s instructions. 
Isolated CD25-, naive Th cells were mixed with different amounts of the bead solution to 
obtain bead-cell ratios of 1:1, 2:1 and 3:1. The proliferation profile of T cells stimulated with 
the indicated bead concentrations appeared to have a similar number of division cycles 
(Fig. 34| A|) as demonstrated by a histogram overlay (Fig. 34| B|). Since CFSE is 
measured by flow cytometry and for this a certain cell number is indispensible, we compared 
different T cell numbers, to estimate the limit of cells/well for an optimal proliferative 
response. We found a T cell number-dependent decrease of T cell proliferation 
(Fig. 34| C|). 
A 
B 
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Fig. 34| Establishment of T cell stimulation with CD3/CD28-coated beads. Plastic beads coated with 
CD3/CD28 mAbs, mimicking APCs, were prepared according to the manufacturers protocol and used in different 
concentrations to stimulate CFSE-stained CD25-depleted naive Th cells (5x10
4
 cells/well; A| and overlay in B|) 
or C| with the recommended concentration (2:1), but varying seeding concentrations of T cells. Cells were 
stimulated for 4 days and proliferation was measured by CFSE dilution and flow cytometry. 
The optimal T cell densities were further defined via measurement of T cell proliferation with 
[3H]-TdR uptake(209). There was an obvious difference between the T cell densities used 
differing in one order of magnitude (Fig. 35|). A higher number of T cells (1x105 cells/well) 
again seemed to inhibit itself, maybe due to shortage of space (cpm = 24,900), whereas 
1x104 cells/well showed a higher proliferative response, with cpm values around 35,000 (Fig. 
35|). Based on these results we decided to use 5x104 T cells/well in further experiments. 
Further, we decided to work with the lowest bead-cell ratio (1:1), as it showed optimal 
stimulation of T cell proliferation. 
 
 
Fig. 35| The proliferative response is 
decreasing with higher T cell densities. 
Naive Th cells (1x10
4
 and 1x10
5
 cells/well) were 
seeded into round-bottom 96-well plates and 
stimulated with CD3/CD28 mAbs (1µg/ml). 
Cells were labeled with [
3
H]-TdR 18 hours 
before harvesting on day 3. Data represent the 
mean of triplicates. 
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5.2.5 Increasing numbers of plastic-adherent dermal cells inhibit the proliferation of 
pan T cells stimulated with CD3/CD28-coated beads 
Using our established parameters we next evaluated, whether they are applicable to verify 
already known data regarding the immunomodulatory potential of BM-MSCs. Further, we 
wanted to investigate the inhibitory potential of plastic-adherent dermal cells on pan T cell 
proliferation. Human embryonic kidney (HEK 293) cells served as a negative control, as they 
do not express HLA-DR or any costimulatory molecules (CD80, CD86) and express low 
levels of HLA-A,B,C (data not shown). For this purpose, cryopreserved dermal cells, BM-
MSCs or HEK cells were thawed, seeded into round-bottom 96-well plates and left to adhere 
o/n. On the next day, freshly isolated pan T cells were stained with CFSE, added to the 
adherent cells and stimulated with CD3/CD28-coated beads (adherent cell:T cell ratios = 
1:50, 1:10 and 1:5). As controls, stimulated (Fig. 36| A|, filled, dark grey histograms) and 
unstimulated T cells were cultured alone and unstimulated T cells were cultured with plastic-
adherent cells (Fig. 36| A|, single peaks at highest fluorescence intensities) and controls 
(HEK 293 cells). Unstained T cells (Fig. 36| A|, filled, light grey histograms) were cultured 
with and without stimulation and adherent cells and controls were cultured without T cells. To 
verify the reliability of the CFSE-based system, the same experiment was set up twice, one 
for CFSE tracking of cell division and another for an [3H]-TdR-based approach (Fig. 36| B|). 
The CFSE proliferation profile of stimulated T cells from cocultures were plotted as red line in 
the overlays of Fig. 36| A|. The immunomodulatory potential of BM-MSCs (MSC:T cell ratio 
= 1:10) could be verified with the CFSE-based cell division tracing method, as the red 
histogram shifted towards the unstimulated cell fraction (Fig. 36| A|, left histogram). Low 
numbers of plastic-adherent total dermal cells (DERMAL CELL:T cell ratio = 1:50) did not 
alter the proliferative response, whereas increasing densities (ratio = 1:10 or 1:5) clearly 
inhibited pan T cell proliferation. As HEK 293 cells did not induce a shift of the red histogram 
towards the unstimulated cell fraction, we could prove that no sterical hindrance is 
responsible for the inhibition of T cell proliferation in this setting. Moreover, a similar inhibiting 
potential of BM-MSCs and dermal cells could be visualized by measuring the [3H]-TdR 
uptake (Fig. 36| B|). BM-MSCs and dermal cells at equal cell numbers inhibited the T cell 
proliferation to a similar extent. 
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Fig. 36| Plastic-adherent dermal cells inhibit pan T cell proliferation in a cell density-dependent manner. 
Both, freshly isolated dermal single cells from juvenile foreskin and, as a positive control, BM-MSCs were 
expanded until passage 2 (P II) and stored in liquid nitrogen. Before coculture, cells were thawed, cultured for 2-3 
days, trypsinized, seeded in different cell numbers into round-bottom 96-well plates [dermal cells (1x10
3
, 5x10
3
 
and 1x10
4
 cells/well) and BM-MSCs and HEK cells (5x10
3
 cells/well)] and left to adhere o/n. On the next day, 
freshly isolated pan T cells (purity > 98%) were added to obtain cell ratios ranging from 1:50-1:5 (adherent cells:T 
cells) and stimulated with Dynabeads (cell-bead ratio = 1:1). BM-MSCs were used as a positive control and HEK 
cells served as negative control. A| CFSE-based approach. In each histogram, unstimulated T cells from 
coculture with the indicated plastic-adherent cells, are plotted (single peak at high CFSE intensities). The filled, 
light grey histograms show T cells without CFSE staining, whereas the dilution profiles in dark grey resulted from 
stimulated T cells alone. The red histogram displays the T cell division cycles after stimulation and 4 days of 
coculture with the mentioned cell types. B| [
3
H]-TdR incorporation assay. The same experimental approach was 
pipetted a second time into another 96-well plate, labeled with [
3
H]-TdR for the last 18 hours of culture and 
harvested on day 4. Shown is one representative experiment out of three. 
5.2.6 Investigating the role of Tregs in MSC-induced T cell suppression 
nTregs are known to suppress a great variety of pathological and physiological immune 
responses in vivo(210). It has been suggested that the functional activity of this cell type is 
related to the expression of the transcription factor FoxP3. To test whether Tregs play a role 
in the decrease of pan T cell proliferation we observed upon coculture with plastic-adherent 
dermal cells, we counterstained CFSE-labeled T cells with an FoxP3 mAb. Indeed, the 
percentage of FoxP3+ cells strongly increased after coculture with BM-MSCs (15.81%), 
compared with CD3/CD28-stimulated T cells alone (5.80%; Fig. 37|). This increase of cells 
with a regulatory phenotype support the concept of a Treg-driven immunosuppression, 
mediated via MSCs. 
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Fig. 37| The percentage of FoxP3
+
 T cells increased after coculture with BM-MSCs. Pan T cells were 
enriched from PBMCs, stained with CFSE, stimulated with CD3/CD28-coated beads and cultured (5x10
4
 
cells/well) with or without BM-MSCs (1x10
3
 cells/well). After 4 days, cells were harvested, beads were removed by 
magnetic forces, T cells were fixed, permeabilized and stained with an AlexaFluor647 labeled mAb directed against 
the intracellular marker FoxP3. Cells were immediately analyzed by flow cytometry and 10,000 cells were 
recorded for each setting. Shown is one representative experiment out of three. 
5.2.7 High numbers of BM-MSCs and umbilical cord blood- (UCB-)MSCs suppress 
the proliferation of CD25-depleted Th cells stimulated with CD3/CD28-coated 
beads 
Most of the published data about the immunoregulatory potential of MSCs include the 
analysis of total PBMCs, pan T cells, CD4+ or CD8+ T cells(119, 211). As our previous results 
indicated an MSC-induced increase of FoxP3+ T cells, we were intrigued, whether MSCs 
could also inhibit the proliferation of naive Th cells, which were depleted of nTregs. To 
address this question, we decided to use MSCs from tissues that have been proven several 
times to have immunosuppressive activity, such as bone marrow and umbilical cord blood. 
Therefore, BM- and UCB-MSCs were cocultured at varying cell densities with CD25-depleted 
naive Th cells, which were stimulated with CD3/CD28-coated beads (MSC:T cell ratios 
ranging from 1:50 to 1:0.5). After 4 days, the CFSE dilution profile was analyzed by flow 
cytometry. Low BM-MSC:T cell ratios (1:50) showed no inhibitory effect on Th cell 
proliferation (Fig. 38| A|, histogram on the left, red line) compared with cell division peaks of 
T cells alone (filled, grey histogram). The white peak on the right displays the unstimulated 
cell fraction. Beginning at MSC:T cell ratios from 1:5 (Fig. 38| A|, middle histogram) and 
higher (right histogram), the proliferation of Th cells was clearly inhibited by BM-MSCs as 
indicated by a shift of the red histogram towards the unstimulated cell peak. The inhibitory 
potential of UCB-MSCs was comparable to BM-MSCs, as low numbers did not alter the 
CFSE division profile or even enhanced the proliferative response to a very low extent, 
whereas increasing UCB-MSC densities showed a clear inhibition of T cell proliferation (Fig. 
38| B|). The finding that MSCs from different sources have the potential to inhibit the 
proliferation of highly purified CD25- Th cells has, thus, been shown for the first time, to our 
knowledge. This would suggest that MSCs have a direct effect on Th cells without the 
interaction of lymphocytes, other than T cells. 
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Fig. 38| BM-MSCs and UCB-MSCs showed a cell density-dependent inhibition of Th cell proliferation in a 
CFSE-based cell division tracking system. CFSE-stained CD25-depleted naive Th cells (5x10
4
 cells/well; purity 
> 96%) were stimulated with CD3/CD28-coated beads (bead-cell ratio = 1:1) and cultured with or without 
irradiated BM-MSCs and UCB-MSCs at different ratios (MSC:T cell ratios ranging from 1:50-1:0.5). Cells were 
harvested on day 4 and CFSE dilution was measured by flow cytometry. A| Low cell numbers of BM-MSCs did 
not alter the proliferation of Th cells after stimulation (red histogram), compared with Th cell proliferation without 
coculture (grey histogram), whereas increasing BM-MSC:T cell ratios resulted in a clear shift of the Th cell division 
profile from coculture towards the unstimulated Th cell fraction (black peak on the very right). B| UCB-MSCs 
showed a similar effect with increasing cell densities. Data are representative of two individual experiments 
performed with two different blood donors. Every setting was done in triplicates. 
5.2.8 Supernatants from BM-MSC and UCB-MSC cultures do not inhibit Th cell 
proliferation 
In addition to coculture assays, supernatants were analyzed, to investigate a potential 
immunosuppressive role of soluble factors that are constitutively secreted by MSCs. For this 
purpose, supernatants from BM-MSCs and UCB-MSCs that were cultured at different cell 
densities in round-bottom 96-well plates, were harvested after 24 hours and transferred into 
a new mictotiter plate. CD25-depleted naive Th cells were stained with CFSE, added (5x10
4 
cells/well) to the supernatants, stimulated with CD3/CD28-coated beads and cultured for 4 
days. Again, proliferating T cells without supernatants were displayed as grey histograms, 
whereas red lines represent T cell proliferation with supernatants. The black peak on the very 
right shows unstimulated T cells. We found that supernatants from BM-MSCs and UCB-
MSCs showed no or only marginal effects on Th cell proliferation (Fig. 39| A| B|). This 
confirmed data published by other groups(128, 131, 212), that endorse the assumption that an 
interaction between T cells and MSCs is required for the secretion of soluble factors involved 
in T cell inhibition. 
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Fig. 39| Soluble factors that might be involved in immunosuppression of T cell proliferation are not 
constitutively expressed by MSCs. CFSE-stained, CD25-depleted, naive Th cells were cultured with 
supernatants of A| BM-MSCs and B| UCB-MSCs (100 µl supernatant of 1x10
3
, 1x10
4
 and 1x10
5
 MSCs/well, 
harvested after 24 hours) and stimulated with CD3/CD28-coated beads. After 4 days, Th cells were harvested 
and analyzed by flow cytometry. Medium derived from any cell density of BM-MSCs and UCB-MSCs did not 
suppress T cell proliferation. Shown is one representative experiment out of two. 
5.2.9 BM-MSCs increase the differentiation of CD25-depleted naive Th cells into 
Tregs upon stimulation with CD3/CD28-coated beads 
Next we wanted to test, whether FoxP3+ T cells are also induced when CD25+ lymphocytes 
were depleted prior to the enrichment process. Highly purified, naive Th cells were cultured 
with or without BM-MSCs and stimulated with CD3/CD28-coated beads or left unstimulated 
for 4 days. After coculture with BM-MSCs, CD4+FoxP3+ T cells increased slightly compared 
with stimulated Th cells alone (Fig. 40|). Surprisingly, stimulation of naive Th cells with 
CD3/CD28-coated beads induced the expression of FoxP3 confirming recently published 
results from other groups, concerning the development of nTregs in the thymus of rodents 
and humans(26). Nevertheless, BM-MSCs were again able to marginally elevate the 
percentage of FoxP3+CD4+ T cells, though not significant, suggesting an enhanced 
differentiation towards the regulatory phenotype upon cell contact. 
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Fig. 40| BM-MSCs marginally increase the percentage of FoxP3
+
 T cells in CD25-depleted naive Th cells. 
CFSE-stained CD25-depleted, naive Th cells (5x10
4
 cells/well) were cultured with or without BM-MSCs (1x10
3
 
cells/well) and stimulated with CD3/CD28-coated beads for 4 days. Compared with the isotype control, 
unstimulated T cells expressed almost no FoxP3, whereas stimulation of these cells enhanced the percentage of 
CD3
+
CD4
+
CD25
+
FoxP3
+
 cells. The percentage of these cells with a regulatory phenotype slightly, but not 
significantly, increased upon coculture with BM-MSCs. Shown is one representative experiment out of two. 
5.2.10 Significant induction of FoxP3 expression in CD25-depleted naive Th cells 
upon coculture with plastic-adherent dermal cells and stimulation with 
CD3/CD28-coated beads 
As we found in previous experiments an inhibitory activity of plastic-adherent dermal cells on 
the proliferation of T cells, which was comparable with the activity of BM- and UCB-MSCs, 
we asked whether also dermal cells have the potential to enhance FoxP3 expression in naive 
CD25-depleted Th cells. For this purpose, total dermal cells from two donors were 
preselected for plastic-adherence, subsequently seeded at low cell densities (1x103 
cells/well) and cocultured with CD25-depleted naive Th cells that were stimulated with 
CD3/CD28-coated beads for 4 days. As negative control, we used HEK 293 cells. Dermal 
cells, but not HEK 293 cells, were able to significantly increase the percentage of FoxP3-
expressing Th cells compared with stimulated T cells alone (Fig. 41|). Again, the 
simultaneous engagement of the TCR complex and CD28 lead to a more than 50% increase 
of FoxP3 in stimulated cells compared with T cells without stimulation. The elevated 
induction of FoxP3 by dermal cells was similar to BM-MSCs, favoring the idea of a related 
pathway. 
 
Fig. 41| Adherent dermal cells enhance the 
expression of FoxP3 in initially naive Th cells 
stimulated with CD3/CD28-coated beads. Plastic-
adherent total dermal cells from two different donors were 
cocultured with CFSE-stained, CD25-depleted naive Th 
cells at a ratio of 1:50. T cells were stimulated with 
CD3/CD28-coated beads and analyzed on day 4 by flow 
cytometry. FoxP3 expression in percent was determined 
by counterstaining with an FoxP3-AF647 mAb and 
specificity was confirmed with an isotype matched control. 
Shown is the mean expression of triplicates from two skin 
donors. 
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5.2.11 Total dermal cells and different dermal MSC subsets are able to induce FoxP3 
in naive Th cells without activation of the CD28-driven costimulatory pathway 
For a long time scientists are debating the need of the engagement of costimulatory 
receptors like CD28. While data have been shown suggesting that costimulation is just an 
enhancer of the TCR signal and does not activate an independent signal transduction 
cascade(7), other studies have reported that anergy or even apoptosis is induced in the 
absence of the CD28-mediated costimulatory signal(213, 214). Further, it has been shown that 
CD28 ligation on naive Th cells in vitro promotes the differentiation towards the Th2 
lineage(215, 216) and that the costimulatory signal is essential for the differentiation of Tregs 
from naive Th cells in the thymus
(217) and their survival and homeostasis in the periphery. To 
further investigate potential effects of dermal MSCs on the differentiation of naive Th cells 
towards the regulatory phenotype, we stimulated isolated Th cells without provision of a 
prominent costimulatory signal and thereby created an environment that is independent of 
well known costimulatory side-effects, as dermal cells and BM-MSCs lack the expression of 
CD80 or CD86. For this purpose, low numbers of irradiated total dermal cells, enriched 
dermal MSC subsets and, as a control, BM-MSCs were seeded into each well of CD3-
coated 96-well plates and cocultured with CFSE-stained, CD25- naive Th cells for 5 days 
(MSC:T cell ratio = 1:50). In Fig. 42| one representative experiment is shown, where skin 
cells were enriched with regard to their expression of CD90, CD271 and CD73, to test 
whether different subsets may induce different percentages of FoxP3+ T cells. First, it is 
important to mention that in all experiments performed, the depletion of CD25+ cells was 
highly successful, with residual CD25+ cell numbers below 0.7%. The lack of CD28 ligation 
led to a low proliferative response and minute numbers of FoxP3-expressing T cells. 
(Fig. 42| B|, T cells w/o stim). Coculture with BM-MSCs, dermal cells and dermal subtypes 
induced a proliferation of T cells, even though no costimulatory signals were provided. Total 
dermal cells were able to induce more than 18% FoxP3+ T cells in initially naive Th cells (Fig. 
42| A|, upper left dot plot) compared with stimulated or unstimulated T cells alone (Fig. 42| 
B|). Unexpectedly, BM-MSCs were able to induce similar numbers of FoxP3+ T cells 
(~18%). A comparison of the different dermal MSC subtypes revealed a tendency for CD90+ 
dermal cells to induce more FoxP3+ T cells than the CD90- cell fraction (Fig. 42| A|, 20.75% 
versus 9.74%). In contrast, a comparison of CD271+ with CD271- dermal cells revealed that 
CD271- cells induced more FoxP3+ T cells than the positive fraction (11.38% versus 8.11%). 
Evaluation of potential differences between CD73+ and CD73- cells showed no trend as data 
varied among the different experiments performed (Fig. 42| C|). It is essential to mention 
that Th cells from every coculture setting had the same number of division cycles (Fig. 42| 
A| C|, histogram overlays). This is one of the most important facts for the numerical 
comparison of changes in expression profiles. 
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Fig. 42| Functional comparison of 
different dermal MSC subsets with regard 
to their FoxP3-inducing capacity. CFSE-
stained, CD25-depleted, naive Th cells (5x10
4 
cells/well) were cultured in CD3-coated 
(1µg/ml) round-bottom 96-well plates with 
different dermal subtypes (CD90
+/-
, CD73
+/-
 
and CD271
+/-
), total dermal cells or BM-MSCs, 
which have been enriched for the respective 
markers, expanded, cryopreserved, thawed 
and used in the experiment (all seeded at a 
density of 1x10
3
 cells/well 24 hours before 
coculture) for 5 days until FACS analysis. 
Shown is one representative experiment out of 
three and 10,000 cells were recorded for every 
fraction. 
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Statistical analysis of all experiments performed, revealed that total dermal cells significantly 
increased FoxP3 expression from a value of 4.09%±1.26 in stimulated T cells alone, to 
15.36%±1.81 after coculture (P<0.01, n=7; Fig. 43|), whereas BM-MSCs induced 
10.98%±2.0 FoxP3+ T cells (P<0.05, n=6). Moreover, we found that CD90+ dermal cells were 
twice as potent to induce FoxP3 compared with CD90- cells (19.14%±4.02 vs. 8.11%±1.70, 
n=3). CD271- dermal cells, on the contrary, showed a higher, though not significant, FoxP3-
inducing capacity than CD271+ dermal cells (14.56%±2.54 vs. 9.62%±2.56, n=3). The 
comparison of the inducing capacity of CD73+/- cells showed a huge variability and no 
tendency was recognizable. With this data we could show for the first time that total dermal 
cells induce T cells with a regulatory phenotype, dependent on the phenotype of the MSC 
subset and independent of the external provision of CD28. In preliminary experiments, we 
could eliminate possible sterical hindrance and validated the induction of FoxP3 through 
dermal cells in the absence of CD28-ligation, using CD3-coated beads (data not shown). 
 
Fig. 43| FoxP3-expressing capacity of total dermal cells, dermal MSC subsets and BM-MSCs. Statistical 
analysis of individual experiments with different skin and T cell donors, revealed a high potency of total dermal 
cells to induce FoxP3 in initially naive Th cells without provision of costimulatory molecules. Comparisons of the 
different dermal subtypes showed a tendency for CD90
+
 cells to induce more FoxP3 than CD90
- 
cells and a 
higher percentage of FoxP3
+
 T cells upon coculture with CD271
-
 cells, compared with CD271
+
 cells, though not 
significant. A Mann-Whitney-U test was used to evaluate significant differences between study and control 
groups. P<0.05 (*) was considered significant, whereas P<0.01 (**) was considered as highly significant. 
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6 Discussion 
Undifferentiated stem cells in post-natal tissues are thought to be responsible for the 
regeneration of injured tissues and the replacement of damaged cells in adult organisms(81, 
218). Human skin, especially the dermis, has been reported to harbor a reservoir of resident 
MSCs, which possess the plasticity to differentiate towards several lineages(219) and express 
a comprehensive marker panel, similar to BM-MSCs. The fact that most studies investigated 
dermal MSCs, which were isolated from hair follicles and the dermal papilla, distincts our 
project, as our aim was the in situ localization and functional characterization of non-follicular 
dermal MSC subsets in glabrous skin. 
Immunofluorescence in situ analysis of common MSC makers, like CD73, CD90, CD105 and 
CD271 demonstrated the dermal occurrence of cells expressing these markers. In human 
skin, an increase of CD271-expressing cells correlates with scar formation, which promotes 
the idea of a tissue-resident stem cell reservoir for tissue regeneration(220). With 
immunofluorescence triple staining, we could verify flow cytometric data showing that (i) 
around 50% of CD271-expressing cells are positive for CD90, (ii) all CD271+ cells are 
positive for CD73 and (iii) the majority of CD73+ cells are CD90+. Further, few cells triple 
positive for all three markers could be identified in the papillary dermis, as well as in the deep 
dermis, which endorses the hypothesis of a scattered distribution of dermal MSCs in adult 
tissues, like skin(221). To better characterize the nature of CD271+ cells, we performed triple 
staining including the markers CD34 and Col-IV. Although, it has been reported that some 
MSCs coexpress the HSC marker CD34, which also stains capillaries in adult dermis(187), no 
CD271+CD34+ cells were detected in dermal sheet preparations. CD271+ cells seemed to 
preferentially colocalize with cells positive for CD34. Recently, it was found that human ESC-
derived CD34+ cells, can differentiate into cells displaying a MSC phenotype, with 
simultaneous downregulation of CD34(188). This would suggest, that MSCs in human skin 
resemble a more terminally differentiated type of progenitor cell, which is also reflected by 
the passage-induced senescence of human MSCs after approximately 40 population 
doublings(222). Interestingly, we could identify several CD271+ cells that coexpressed Col-IV, 
which is known to specifically stain the basement membranes of blood vessels, lymphatics 
and the peripheral nervous system, and colocalized in deep dermis with cells expressing 
CD34. Few studies have reported the expression of Col-IV in MSCs(223, 224), all of them 
dealing with bone marrow-derived cells. Although Col-IV expression in healthy human skin 
and skin tumors has been already reported(189, 190), the presence of CD271+Col-IV+ cells in 
human skin, is novel to our knowledge. Our findings strongly suggest a perivascular location 
of dermal MSCs and support the hypothesis for BM-MSCs that have been found to form a 
unique perivascular niche(110, 138, 225) as well. 
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Investigating the morphology of plastic adherent dermal cells at the single-cell level, we 
found that they display a typical fibroblastoid appearance. They highly expressed CD73, 
CD90 and CD105, which confirmed previous flow cytometric data(219). Few adherent cells 
also expressed -SMA, an actin isoform typical for smooth muscle cells in vascular walls, 
especially in the cytoplasm of pericytes(226). Evidence, however, has been provided that 
mesenchymal progenitor cells of different origins can also express this marker(227). 
Surprisingly, the transcription factor Oct-4, the master regulator of self-renewal in 
undifferentiated ESCs(228), was also expressed in a few adherent dermal cells. Although the 
selected Ab stains both slicing products, namely Oct-4A, which is specific for ESCs and Oct-
4B that is expressed in many other cells too, our data favor the existence of somatic 
multipotent progenitor cell populations within the skin. This hypothesis is supported by our 
observation that just the nuclei were positive for Oct-4, whereas the unspecific factor Oct-4B 
is mainly localized in the cytoplasm(229). The two different morphologies of cultured CD271+ 
cells, on the one hand fibroblastoid, but on the other hand almost neuronal/glial-like 
persuaded us to investigate in situ, possible correlations with neural crest-derived cells. 
Double staining with a CD56 mAb confirmed the expression of CD271 and CD56 on 
peripheral nerve endings in the dermis(164, 230). MSCs that express CD271 in combination with 
CD56 have also been found in human bone marrow and are thought to resemble a distinct 
subtype of MSCs with high clonogenicity(106, 201). However, CD271 is also known to be a 
marker for migrating neural crest-derived Schwann cell progenitors and has been reported to 
be coexpressed with CD56 in early Schwann cell development during scar formation(220). 
Together with the finding that Schwann cells can differentiate into -SMA-expressing 
myofibroblasts, this allows the assumption that neural crest progenitors and MSCs from 
peripheral tissues share more features than initially thought. Further, BM-MSCs are believed 
to have a neural predisposition(194), and have been reported to express neuronal markers, 
like -III-tubulin, which is mainly expressed in neurons of the peripheral and central nervous 
system, but was also found to be a general component of the mitotic spindle of various cell 
types(193), or glial markers, like GFAP. We showed the existence of CD271+-III-tubulin+ cells 
and CD271+GFAP+ cells within the dermis, and a preferred colocalisation of CD271+ cells to 
cells expressing these neuronal/glial markers. Thus, our data indicate that dermal MSC 
subtypes and pericytes are related cells(231). The close association of dermal MSCs to skin 
vasculature, in combination with the expression of adhesion proteins, like CD90, which allow 
the interaction with endothelial cells(133), and the expression of the pericyte specific marker -
SMA, supports our hypothesis. The successful isolation of MSCs from the subendothelial 
area of the umbilical vein(232, 233), support our conclusion. The fact that both, pericytes(234) and 
BM-MSCs express CD271(231), strongly suggests that these cells derive from a common 
ancestor(231), maybe originating from the neural crest, which harbors migratory cells showing 
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multipotency before and after migration(235). The close vicinity to endothelial cells also 
suggests a facilitated interaction of MSCs with circulating lymphocytes from the blood 
stream, with an enhanced probability of immunomodulatory activities in situ. The absence of 
HLA-DR expression and the lack of costimulatory molecules, like CD80/86, renders dermal 
MSCs hypo-immunogeneic. 
Using a CFSE-based division tracing coculture system, which has been adapted for our 
experiments during this thesis, we were able to confirm the suppressive activity of plastic-
adherent dermal cells(148, 167, 236) and allogeneic BM-MSCs on total T cell proliferation, 
stimulated via CD3/CD28-coated beads. In accordance with other studies(148, 167), we found 
a cell density-dependent inhibition of T cell proliferation by plastic-adherent dermal cells, 
starting at ratios around 1:10 (dermal cell:T cell) and showing strong T cell inhibition at the 
ratio 1:5, which was comparable with BM-MSCs(111). Interestingly, low numbers of dermal 
cells and BM-MSCs (ratio=1:50) seemed to have no effect on T cell proliferation and even 
had stimulating activity. This enhancement of lymphocyte proliferation with low numbers of 
BM-MSCs has been reported previously(204) for ratios lower than 1:10(236), in allogeneic, 
mitogenic or interleukin-induced proliferation models(211). Regarding CD8+ and CD4+ T cells, 
low numbers of BM-MSCs (ratio=1:50) in combination with the addition of IL-2, IL-7 and IL-15 
has been reported to significantly enhance lymphocyte proliferation. As IL-2, in combination 
with TCR complex stimulation, is known to be suitable for the efficient clonal expansion of 
Tregs(49) and IL-7 and IL-15 are also involved in the development and function of Tregs(49), 
the observed increase of lymphocyte proliferation might be based on proliferating Tregs. In 
line with this idea is the finding that human dermal fibroblasts promote the proliferation of 
FoxP3+ Tregs upon addition of soluble IL-2 and IL-15(237). Numerous studies, dealing with the 
effect of MSCs on Tregs, are enhancing the perception that MSCs from bone marrow and 
other tissues recruit, regulate and expand Tregs(128, 129). We could show via analysis of the 
CFSE dilution profile and counterstaining of FoxP3 that FoxP3+ T cells strongly increase 
upon coculture with BM-MSCs, which suggests a possible role of Tregs in T cell inhibition. 
With our data we confirmed the results from other groups, which used total PBMCs, total T 
cells, CD4+ and CD8+ T cells(129). As we were interested whether nTregs are induced to 
multiply by MSCs or whether naive Th cells are induced to differentiate towards a regulatory 
phenotype, highly enriched CD25-depleted, naive Th cells were cocultured with BM- and 
UCB-MSCs. Even highly purified T cells were clearly inhibited in their proliferation upon 
coculture with BM- and UCB-MSCs. As we could not see any effect with conditioned media 
from cultured BM- or UCB-MSCs, we propose that the inhibition is based on a cross-talk 
between T cells and MSCs. Hence, possible soluble factors are not secreted constitutively. 
Analysis of the possible induction of FoxP3 revealed that stimulation with CD3/CD28 alone 
induced the expression of FoxP3 in initially CD25-depleted naive Th cells. Coculture with 
dermal cells or BM-MSCs, however, slightly but not significantly increased the percentage of 
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FoxP3+ T cells. The role of CD28 signaling for the generation of nTregs in the thymus and for 
Treg survival and homeostasis in the periphery has been demonstrated for mice(217) and 
humans(238). Although, CD28 ligation via CD80 or CD86 is not obligatory for the induction of 
effector T cell proliferation, it has been shown that additional costimulatory signals generally 
enhance and fasten T cell activation, proliferation, cytokine production, survival and up-
regulate anti-apoptotic proteins, which leads to more vigorous T cell responses(239). In 
contrast, it has been shown for Tregs to have different costimulatory requirements than 
effector T cells, as postthymic Tregs depend on signals induced by CD28 ligation to expand 
and maintain their function(238). We could show that only low numbers of CD25-depleted 
naive Th cells enter the cell division cycle upon stimulation with CD3 only, whereas the 
percentage of dividing cells decreased with increasing purity of naive Th cells. Interestingly, 
we found a strong induction of T cell proliferation upon coculture with total dermal cells, 
dermal subsets and BM-MSCs, although these cells lack the expression of CD80 and CD86. 
Using counterstaining of FoxP3 in CFSE-labeled initially FoxP3-CD25-CD4+ T cells, we were 
able to visualize the induction of FoxP3 expression upon coculture with dermal cells and BM-
MSCs. The finding that dermal cells had a higher inducing capacity than BM-MSCs, suggests 
an important role of dermal cells in the peripheral generation of iTregs. One of the most 
prominent candidates for the substitution of CD28 in the generation of Tregs, is TGF-. It 
was shown in multiple in vitro experiments that TGF-, together with a stimulus for the TCR 
complex, is a potent trigger for FoxP3-induction. For our in vitro system, we can exclude that 
dermal cells produce this growth factor, as we showed previously that TGF- is primarily 
expressed in the epidermis and practically absent in human dermis(240). Nevertheless, the 
induction of TGF- expression in dermal cells upon coculture with T cells cannot be 
excluded, but signals induced through CD28-ligation are still vital for the survival and 
maintainance of Tregs(241). Further, one can speculate that CD80 or CD86 expression could 
be induced upon coculture with T cells, which we were able to refute in preliminary 
experiments (data not shown). However, the question whether these FoxP3+ T cells are 
functionally equivalent to nTregs remains and still has to be elucidated. 
In summary, we showed the in vivo identity of dermal MSC subsets, preferentially located 
close to the skin vasculature, suggesting their homing in a perivascular niche. This would 
allow dermal MSCs to directly interact with lymphocytes. Moreover, we demonstrated new 
insights in peripheral Treg generation through dermal cells and could show a trend towards 
dermal subtypes, to induce more FoxP3 expression than others. This strongly suggests a 
homeostasis-driven proliferative response induced by the interaction of naive Th cell with self-
peptide-presenting APCs in the periphery(242-245) with simultaneous induction of FoxP3 by 
local tissue MSCs for a rapid induction of Tregs, via bypassing the regulatory checkpoint of 
CD28 engagement or binding of CD28 through other ligands than CD80/CD86. 
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